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Family history has been called the “cornerstone of individualized disease 
prevention” but it is underutilized in clinical practice.  In order to use it more 
effectively, its role in assessing risk for disease needs to be better quantified and 
understood. Family history has been identified as an important risk factor for 
colorectal cancer (CRC) and risk prediction in CRC is potentially worthwhile because 
of the possibility of preventing the disease through application of individualized 
screening programs tailored to risk. The overall project objective was to explore how 
family history can be better utilized to predict who will develop CRC.  First, we used 
the Utah Population Database (UPDB) to define familial risk for CRC in more detail 
than has previously been reported. Second, we explored whether individuals at 
increased familial risk for CRC or at increased risk based on other risk factors such 
as a personal history of CRC or adenomatous polyps, are more compliant with 
screening and surveillance recommendations using colonoscopy than those who are 
at normal risk.  Third, we measured how well family history can predict who will 
develop CRC over a period of 20 years, using family history by itself as a risk factor, 
and also in combination with the risk factor, age.  We found that increased numbers 
of affected first-degree relatives influence risk much more than affected relatives 
from the second or third degrees. However, when combined with a positive first-
degree family history, a positive second- and third-degree family history can 
 
 
significantly increase risk.  Next, we found that colonoscopy rates were higher in 
those with risk factors, according to risk-specific guidelines, but improvements in 
compliance are still warranted. Lastly, it was determined that family history by 
itself is not a strong predictor of exactly who will acquire colorectal cancer within 20 
years.  However, stratification of risk using absolute risk probabilities may be more 
helpful in focusing screening on individuals who are more likely to develop the 
disease. Future work includes using these findings as a basis for a cost/benefit 
analysis to determine optimal screening recommendations and building tools to 
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Risk prediction is an area of growing interest and attention in medicine and 
biomedical informatics, particularly through the development and application of 
statistical and machine learning models.  In 1976, the first risk prediction model for 
a chronic disease was published: the Framingham Coronary Risk Prediction Model.1  
This model predicted an individual’s risk for developing heart disease based on 
factors such as serum cholesterol level, blood pressure, smoking history, 
electrocardiogram results, and glucose intolerance.  Work on the original model has 
been modified and expanded over the years to include a number of risk score profile 
tools that are used by physicians to make decisions about prevention and 
treatment.2-7   
Predicting who is at risk for cancer has been a particular focus of effort, based 
on the prevalence and burden of this group of diseases.  Risk prediction models for 
breast cancer were developed in the late 1980s and early 1990s.  These models used 
risk factors such as age, age at menarche, and family history of breast cancer to 
predict the absolute risk that an individual would develop the disease over a 
particular period of time.8, 9  Since then, breast cancer models have been updated 





13  Risk models for other cancers such as colorectal, lung, prostate, ovarian, and 
melanoma have been developed as well.14-18  The major applications of models for 
predicting risk and susceptibility in cancer are: (1) Identifying individuals at high 
risk (for appropriate screening), (2) Improving clinical decision making (e.g., genetic 
counseling), (3) Designing population prevention strategies, (4) Estimating the cost 
of the population burden of disease, (5) Enabling the creation of benefit-risk indices, 
and (6) Planning intervention trials (e.g., chemoprevention).19  
The development and application of risk models are enabled by information 
technology and would be more difficult to implement without the assistance of the 
modern computer.  The field of biomedical informatics may be considered an 
important contributor to risk modeling through the integration of medicine, 
computer science, information science and data management, and statistical 
analysis.  However, a particularly topical area where biomedical informatics plays a 
key role is the application of risk prediction models for use in decision support in 
electronic medical record (EMR) systems.  One may envision an EMR system with 
comprehensive, integrated decision support that uses data from a patient’s record 
and other sources to assess the risk for developing a particular disease and provides 
the clinician and patient with actionable recommendations for mitigating the 
potential risk. 
This application of a risk model may also be considered within the domain of 
personalized medicine.  This is a medical model of growing interest that leverages 
information about an individual patient, particularly genomic and proteomic, in 





individual patient.20  This movement is being facilitated by advances in genetic 
testing and molecular profiling technologies and aims to address the deficiencies of 
therapies that are primarily based on epidemiological studies of large cohorts.  
Currently, known factors such as family history, environment, social circumstances, 
and behavior are considered by clinicians in creating personalized treatment plans.  
While these risk factors will continue to be useful in the future, it is likely that 
prediction will further be enhanced by molecular profiling, providing the capability 
to address more individual differences and tailor specific and efficacious prevention 
and treatment.   
 
 
1.1   Family history 
Even as specific risk factors for disease are discovered through molecular 
profiling or other research methods, there is clearly benefit to be gained from the 
exploration of risk factors such as family history.  When more sophisticated 
molecular profiling techniques are ready for clinical implementation, experts still 
believe family history will be play an important role in stratifying a patient’s risk.21  
It has been called the “cornerstone of individualized disease prevention” and is a 
“free, well-proven, personalized genomic tool” that captures many of the interactions 
between multiple genes and environmental factors.21   
Despite the promise of the role of family history, there is evidence that it is 
currently underutilized in clinical practice.   There are several barriers present.  
First, patients are sometimes unaware of family members’ health histories, even in 





clinicians may fail to recognize the potential value as it can be difficult to quantify 
and understand risk.  Even those clinicians who understand the importance of 
family history in disease, are under extraordinary time pressure during an office 
visit that impacts their ability to collect, document and discuss the information and 
risk with the patient.  Although family history may get documented in the patient’s 
record, and sometimes electronically in an EMR, there is a lack of tools to help 
analyze and interpret the resulting risk.  Improving or finding new methods to 
capture and utilize family history information is a worthwhile challenge with a clear 
role for informatics.  In order to more effectively use family history in clinical 
practice, its role in assessing risk for disease needs to be better quantified and 
understood, particularly in the context of other risk factors. 
Studying the role of family history in disease can be challenging because of 
the reasons mentioned above, most notably because it is not captured with 
consistency in clinical practice, let alone in a standardized way.  Epidemiological 
studies have captured family history information at times, most often for first-
degree relatives.  Data are almost always self-reported so recall bias and inaccuracy 
are potential issues.  In the state of Utah there is an unusual opportunity to 
investigate the influence of family history in disease, and particularly cancer, 
through the Utah Population Database (UPDB).  The UPDB is a population-based 
genealogical resource that includes statewide cancer registry records from the Utah 
Cancer Registry (UCR), and other records such as birth and death certificates, 
driver’s license data, and inpatient and outpatient medical and billing records from 





based on genealogical records from the Utah Family History Library and contains 
genealogies for the original Utah pioneers (members of the Church of Jesus Christ of 
Latter-day Saints) and their modern-day descendants.23, 24  This resource will be 
described in more detail in subsequent chapters, but it is worthwhile to note that 
this resource does much to address the limitations previously mentioned concerning 
family history availability and quality.  The original Utah Genealogy included 
records of 1.6 million persons who were part of 6- to 7-generation pedigrees.22 
Although not all have linked genealogic data, the UPDB includes information for 
approximately 7 million persons today with some pedigrees >11 generations deep.  
The link between the UCR and the Utah genealogy is a major strength of the UPDB.  
The UCR was established in 1966 and includes records dating back to 1952 and 
since 1973 has been part of the Surveillance, Epidemiology, and End Results 
network of National Cancer Institute registries.  Among those with cancer records in 
the UCR, 94% link to ≥1 records in the UPDB and 64.2% have family information. 
Cancer records are coded by disease site according to the International Classification 
of Diseases of Oncology and include information on site, stage, grade, age at 
diagnosis, histology, and patient survival.25  In cases in which a person has multiple 
cancers the UCR is careful to report only independent primary sites of cancer. 
While the UPDB is an extraordinary resource on its own, in recent years a 
link has been created between the UPDB and electronic records from Intermountain 
Healthcare.   Intermountain Healthcare provides medical care for a large percentage 
of the Utah population and also has a long history of electronic documentation of 





data for visits, hospital stays, diagnoses, procedures, laboratory orders and results, 
medications, problems, and clinical findings, as well as various unstructured 
narrative notes and reports.  Many of the individuals with genealogy data in the 
UPDB also have health care records at Intermountain. This has provided an 
opportunity to link high-quality family history data from the UPDB with clinical and 
billing data from Intermountain, enabling research previously not possible. 
The UPDB has strict rules concerning appropriate uses of the data, and they 
cannot be used for clinical care purposes.  For example, even if a group of individuals 
was identified at high risk for a particular disease based on family history in the 
UPDB, they could not be contacted for the purpose of clinical care or intervention 
due to the restrictions imposed by the legislation that created the resource.  
However, despite this limitation, the results of research based on UPDB data may 
help to confirm and/or quantify the value of utilizing self-reported family history 
data in clinical practice.  It also may help to set a standard against which to 
benchmark other approaches for collecting family history.   
 
1.2   Colorectal cancer 
CRC is the second leading cause of death among cancers.  In 2009, it was 
estimated that 147,000 cases would be newly diagnosed and that 50,000 deaths 
would be caused by the disease.26  The lifetime risk of acquiring CRC is 5.5% for men 
and 5.1% for women.  Although rates have slowly been declining since 1985, the age-
adjusted incidences per 100,000 in the population are 61.2 and 44.8, for men and 





colorectal cancer (CRC) is a particular area of interest in risk prediction because 
screening through a method like colonoscopy can detect and remove precancerous 
polyps before they can progress into cancer.27, 28 Despite the declining incidence, 
screening rates are still not at recommended levels.   It has been estimated that over 
half of deaths from CRC could be prevented through early detection.29  Increased 
surveillance in those at increased risk may lead to the detection of more cases, and 
therefore a potentially greater mortality reduction, than uniform surveillance of the 
entire population.30   
Family history has been well established as a risk factor for CRC.31-34  As 
mentioned previously, risk models have been developed for CRC, although with a 
few exceptions,14, 35, 36 they most often address highly-genetic forms of the disease 
such as Lynch syndrome (LS, also known as  hereditary nonpolyposis colorectal 
cancer (HNPCC)) or familial adenomatous polyposis (FAP), which represent a 
relatively small percentage of CRC cases.37-39  Although it is clear that rare forms of 
the disease such as LS and FAP are highly genetic, it has been established that 
genetics still play a role in a fair number of other cases of the disease.  However, the 
majority of CRC cases are still considered sporadic without a known genetic 
contribution. 
CRC is an example of a disease where risk modeling is potentially very useful 
because screening and treatment for the disease can both be financially costly. 
Screening through a technique such as colonoscopy, while effective, also has medical 
risks.  A comprehensive decision model that takes into account the risk of acquiring 





costs of screening and treatment would be particularly useful in determining the 
“best care at the best cost” based on an individual’s unique set of risk factors. 
 
1.3   Study objectives 
The overall goal of the project was to explore how family history can be better 
utilized to improve clinical care; specifically better predicting who will develop CRC.  
The strength of family history and cancer data resources available through the 
UPDB, electronic medical records from institutions such as Intermountain 
Healthcare, and local interest and expertise in clinical genetics, genetic 
epidemiology, and clinical decision support, created an ideal environment for 
exploring this topic.  The project was divided into three phases that addressed 
different aspects of predicting risk for CRC.  The objective of the first phase was to 
use the UPDB to define familial risk for CRC in more depth than has previously 
been reported.  Typically in studies of family history and disease only first-degree 
relatives (e.g., parents, siblings, children) are considered.  A principal reason may be 
that studies often use self-reported family history data and it may be difficult for 
probands to obtain reliable data on extended relatives from the second (e.g., aunts 
and uncles, grandparents) or third degrees (e.g., great-grandparents, cousins).  Our 
hypothesis was that the influence of affected relatives from the second and third 
degrees may have a significant impact on relative risk for CRC.  Another objective of 
this phase was to produce familial relative risk estimates for a large number of 
different “constellations” or combinations of affected first-, second-, and third-degree 





history.  The sheer size of the UPDB, with respect to numbers of individuals with 
high-quality family history and with and without CRC, allowed investigation of a 
large number of different constellations of affected relatives.  This first phase of 
research provided a foundation for subsequent phases that included subsets of the 
same UPDB population and also capitalized on the familial relative risk estimates 
for various constellations. 
 The second phase of the project used the link between the UPDB and 
Intermountain Healthcare medical data.  This phase involved an exploration of 
whether individuals at increased familial risk for CRC or at increased risk based on 
other risk factors such as a personal history of CRC or adenomatous polyps are more 
compliant with screening and surveillance recommendations using the colonoscopy 
modality than those who are at normal risk.  A group of living individuals who had 
both UPDB records and Intermountain data, and who had been seen as an inpatient 
or outpatient within the last 5 years at Intermountain Healthcare, were included in 
this study.  Intermountain records provided coded and/or structured data on risk 
factors such as a previous history of CRC or adenoma and dates of procedures such 
as colonoscopy. Well-known screening and surveillance guidelines for those at 
increased risk based on these risk factors were adapted in order to measure 
compliance.  The hypothesis was that individuals with a positive family history or 
other risk factors would be screened more frequently than those at normal risk, 
according to accepted guidelines.  
 The objective of the third and final phase of the project was to determine the 





the objective was to measure how well family history can predict who will develop 
CRC over a period of 20 years, using family history by itself as a risk factor, and also 
in combination with the risk factor of age.  Although family history has been well-
established as a risk factor for CRC, relative risk does not reflect that the incidence 
of CRC may be considered low overall in the population.  Considering this fact, the 
absolute risk for the disease may or may not be strongly influenced by family 
history.  However, the hypothesis was that family history does have predictive value 
that is clinically worthwhile, particularly for those at the highest levels of familial 
risk. 
 
1.4   Summary 
Risk prediction is an area of growing interest in biomedical informatics and 
medicine and the increasing availability of data has fueled this interest.  Among 
diseases where risk prediction has been applied, cancer has been a particular area of 
focus considering its scope and impact.  Among cancers, CRC is particularly 
interesting to researchers in risk prediction because of the possibility of preventing 
the disease through early screening.  Family history has been identified as an 
important risk factor for CRC and plays a potentially important role in risk 
prediction.  Even when more specific molecular risk factors are discovered for CRC 
and other cancers, it is likely that family history will still be worthwhile to consider.  
However, family history is currently underutilized in clinical practice for a variety of 
reasons including lack of patient awareness of family member medical histories, lack 





collect and make use of the data in clinical practice, and lack of tools such as risk 
models and clinical decision support to help estimate and interpret risk and provide 
recommendations.  Although family history is considered one of the most important 
risk factors for CRC, it has not been clear whether (1) a very large study using 
population-based family history and cancer registry records would find differences in 
relative risk from published estimates, (2) extended relatives affected with CRC 
make a significant contribution to risk, (3) those with a positive family history and 
other clinical risk factors are more likely to have been screened according to common 
guidelines, and (4) family history is able to predict accurately who will get CRC over 
a 20-year period, particularly in certain risk categories.  The following chapters 
present three papers that address the objectives and research questions that have 
been outlined above. 
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BACKGROUND & AIMS: Colorectal cancer (CRC) risk
estimates based on family history typically include only
close relatives. We report familial relative risk (FRR) in
probands with various combinations, or constellations,
of affected relatives, extending to third-degree. METH-
ODS: A population-based resource that includes a com-
puterized genealogy linked to statewide cancer records
was used to identify genetic relationships among CRC
cases and their first-, second-, and third-degree relatives
(FDRs, SDRs, and TDRs). FRRs were estimated by com-
paring the observed number of affected persons with a
particular family history constellation to the expected
number, based on cohort-specific CRC rates. RESULTS:
A total of 2,327,327 persons included in !3 generation
family histories were analyzed; 10,556 had a diagnosis of
CRC. The FRR for CRC in persons with!1 affected FDR
! 2.05 (95% CI, 1.96–2.14), consistent with published
estimates. In the absence of a positive first-degree family
history, considering both affected SDRs and TDRs, only
1 constellation had an FRR estimate that was signifi-
cantly "1.0 (0 affected FDRs, 1 affected SDR, 2 affected
TDRs; FRR ! 1.33; 95% CI, 1.13–1.55). The FRR for
persons with 1 affected FDR, 1 affected SDR, and 0
affected TDRs was 1.88 (95% CI, 1.59–2.20), increasing to
FRR ! 3.28 (95% CI, 2.44–4.31) for probands with 1
affected FDR, 1 affected SDR, and !3 affected TDRs.
CONCLUSIONS: Increased numbers of affected
FDRs influences risk much more than affected SDRs
or TDRs. However, when combined with a positive
first-degree family history, a positive second- and
third-degree family history can significantly increase
risk.
Keywords: Colorectal; Relative Risk; UPDB.
Colorectal cancer (CRC) is the third most commoncancer diagnosed in the United States and the sec-
ond leading cause of death among cancers. It is estimated
that in 2008 alone 148,810 people will be diagnosed with
CRC and 49,960 will die of the disease.1 Screening strat-
egies such as fecal occult blood test, flexible sigmoidos-
copy, and colonoscopy, among others, have been proven
effective in reducing the incidence and mortality of the
disease.2 Although CRC incidence and mortality rates
have been declining, most US adults are still not being
screened or receiving regular screenings appropriate for
their age or risk status.3,4 Knowledge of increased risk can
be a motivating factor in making decisions about screen-
ing.5 If a greater proportion of adults received regular
screenings appropriate for their risk, it is likely that
additional reductions in CRC incidence and mortality
could be achieved.
Family history is a well-established risk factor for
CRC.6 Many studies have estimated familial risk of CRC
and consistently shown that having !1 affected first-
degree relative (FDR) doubles a person’s risk of CRC.6–10
A recent random-effects analysis that pooled relative risk
estimates for CRC from multiple published reports was
presented by Butterworth et al in 2006.11 Although this
meta-analysis comprehensively included the relevant
published research to date, limitations in the source
studies bring to light additional questions. Most studies
focused on categorizing!1 affected FDR. Additional risk
factors in other studies included affected second-degree
relatives (SDRs), age of onset in affected FDRs, sex, and
relationship type (ie, parent or child, sister or brother).
Although data on FDRs are the easiest to obtain from
patients and may be the most clinically relevant, it is
currently not known what impact more distant affected
relatives have on risk. Just as important, the risk stem-
ming from various combinations, or “constellations,” of
affected relatives has not been adequately explored. Pa-
tients frequently present to physicians reporting multiple
relatives affected with colorectal cancer. These often in-
clude affected relatives from first-, second-, and third-
degree relationships and might include positive family
history from both parents (Figure 1 contains a pedigree
diagram to show family relationships and degrees). Phy-
sicians presently have little if any data on how to estimate
Abbreviations used in this paper: CRC, colorectal cancer; E, ex-
pected; FDR, first-degree relative; FRR, familial relative risk; O, ob-
served; SDR, second-degree relative; TDR, third-degree relative; UCR,
Utah Cancer Registry; UPDB, Utah Population Database.



















risk for such patients and thereby to determine appro-
priate screening.
The objective of our study was to expand the scope of
previous CRC familial risk research to measure and re-
port familial relative risk (FRR) estimates for a variety of
specific constellations of family history. This investiga-
tion allows risk levels to be assigned for most combina-
tions of affected relatives, thus assisting the physician in
making more appropriate screening recommendations.
To accomplish this we examined first-, second-, and
third-degree risks in a population-based resource with a
computerized genealogy linked to statewide cancer reg-
istry records. This resource, the Utah Population Data-
base (UPDB), provides an unusual opportunity to inves-
tigate the relative risk of CRC in relatives in a large
population at a more detailed level than has been previ-
ously published.
Data
The UPDB is a population-based, computerized
genealogic resource for Utah containing multiple record-
linked data sources, including cancer registry records,
birth and death certificates, and driver’s license data, that
has also been linked to inpatient and outpatient records
from the University of Utah Health Sciences Center. The
UPDB contains genealogies for the original Utah pio-
neers (members of The Church of Jesus Christ of Latter-
day Saints, or Mormons) and their modern-day descen-
dants and was created in the early 1970s with data from
the Utah Family History Library.12,13 The original Utah
Genealogy included records for 1.6 million persons who
were part of 6- to 7-generation pedigrees.14 Today, the
UPDB includes information for approximately 7 million
persons, although not all have linked genealogic data.
Some pedigrees are now "11 generations deep.
Of particular interest for this study were Utah Cancer
Registry (UCR) records linked to the Utah genealogy. The
UCR is a statewide cancer registry established in 1966
that includes records dating back to 1952. Since 1973 the
UCR has been part of the Surveillance, Epidemiology,
and End Results network of National Cancer Institute
registries. Ninety-four percent of persons with cancer link
to !1 records in the UPDB and 64.2% have family infor-
mation. The UCR cancer records are coded by disease site
according to the International Classification of Diseases
of Oncology and include information on site, stage,
grade, age at diagnosis, histology, and patient survival.15
The UCR is careful to report only independent primary
Figure 1. Sample pedigree structure illustrating some example relationships including first-, second-, and third-degree relatives (FDR, SDR, TDR).
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sites of cancer in cases in which a person has multiple
cancers.
Previous demographic and genetic analyses have
shown that the population recorded in the UPDB is
genetically representative of US white and northern Eu-
ropean populations16–19 with a low-to-normal level of
inbreeding.20 Most Utahns are members of The Church
of Jesus Christ of Latter-day Saints, which has religious
proscriptions against the use of coffee, tea, alcohol, and
tobacco. Utah is among the states with the lowest rates of
cancer,1 and much lower smoking rates may play a role.21
Although the UPDB contains records for approxi-
mately 7 million people, this study used a subset of 2.3
million persons who were part of!3 generations of Utah
genealogy data and descendants of original Utah pio-
neers.
Access to the UPDB is governed by the Utah Resource
for Genetic Epidemiology which was created in 1982.22
The Utah Resource for Genetic Epidemiology and Uni-
versity of Utah Institutional Review Board approvals were
obtained to access these data and to conduct this re-
search. Names and other identifying information were
not available to the authors to protect the privacy of
persons in the UPDB.
Materials and Methods
FRR in relatives represents the ratio of the risk for
a disease among relatives of probands to the risk for the
disease in the general population. It is estimated as the
number of observed (O) cases among relatives of pro-
bands divided by the number of expected (E) cases among
the relatives (ie, FRR ! O/E). The expected number of
cases among relatives is estimated by using population
rates. This ratio, also known as a “standardized morbidity
ratio,” is considered a reasonable approximation of true
relative risk when the prevalence of the disease and the
true relative risk in the population are low.23 This
method of estimating FRR in relatives has been used in
previous UPDB analyses of familial risk in cancer24,25 and
other diseases.26,27
All persons in the UPDB who are part of !3 genera-
tions of Utah genealogy data (2.3 million) were assigned
to 1 of 264 cohorts based on characteristics that may
influence the quality and quantity of genealogic data:
birth year (5-year groups), sex, amount of ancestral gene-
alogy ("6 ancestors or not), and birthplace (Utah or not
Utah). Internal, cohort-specific CRC rates were calculated
by summing the number of CRC cases in each cohort and
dividing by the total number of UPDB persons in that
cohort. In this study a proband was defined as a person
who has a particular constellation pattern of affected
relatives (eg, 1 affected FDR, 0 affected SDRs, and !3
third-degree relatives [TDRs]), whether the proband is a
CRC case himself or herself. All persons among the 2.3
million with a particular constellation pattern of affected
relatives were considered probands for the corresponding
FRR calculation.
After selecting a constellation pattern and determining
the group of probands who fit the pattern, the number of
observed CRC cases (O) in the group of probands is
counted by cohort, without duplication. The expected
number of cancers (E) among the defined set of probands
is estimated by using the following formula: E ! # Pi $
Ci/Ni (for i between 1 and 264), where Pi, Ci, and Ni are the
number probands, the number of CRC cases in the
UPDB, and the number of persons in the UPDB, respec-
tively, in the ith cohort group. This method assumes that
the morbidity and migration rates for a given cohort of
probands is on average the same as that for an equivalent
cohort of persons in the UPDB.
For FRR ! O/E, P values were calculated, based on the
null hypothesis FRR! 1.0 and the alternative hypothesis
FRR "1.0. An assumption was made that the number of
observed cases followed a Poisson distribution with the
mean equal to the expected number of cases. Confidence
intervals for the FRRs were estimated by the method
given by Agresti.28
The selection of constellation patterns for which to
calculate FRRs was based on common analyses in previ-
ous studies11 and consensus of the authors. The first
group of analyses performed in this study was based on
systematically increasing numbers of relatives within
each degree, for instance, calculating FRR for those with
1 affected FDR (irrespective of affected SDRs and TDRs),
then 2 affected FDRs, then 3, and so forth. Because in a
clinical setting individual patients are expected to have
various degrees of family history knowledge, we calcu-
lated relative risks for the following situations: (1) only
first-degree family history known, (2) only first- and sec-
ond-degree family history known, and (3) first-, second-,
and third-degree family history known. Additional con-
stellation patterns and associated FRR estimates are con-
tained in Supplementary Tables A and B (see supplemen-
tal material). Variations in age at diagnosis of CRC for
the affected FDRs and SDRs (Supplementary Tables C
and D) were also considered. FRRs for !1 affected FDRs
by type of FDR (eg, mother/father, brother/sister, parent/
sibling/child, offspring, and male/female) were estimated
as well as the FRR for having both an affected mother
and an affected father (Supplementary Table E). We also
estimated FRRs based on whether a proband’s family
history was concentrated solely on one side of a family
versus both sides (Supplementary Table F).
Results
A total of 2,327,327 persons included in !3 gen-
eration family histories were included in this analysis.
Among these persons included in the study, 10,556 were
identified with a primary diagnosis of CRC. On the basis
of consensus among the authors, an FRR estimate !2.0















March 2010 FAMILY HISTORY AND RISK FOR COLORECTAL CANCER 879
18
clinically relevant cutoff for elevated risk. All of the con-
stellations producing FRR estimates meeting this clini-
cally relevant criteria are presented in Tables 1–5, along
with selected others that are presented for comparison.
First-Degree Risk
The FRR estimates for probands with increasing
numbers of affected FDRs, without respect to SDRs or
TDRs, are shown in Table 1. The most commonly pub-
lished FRR is for !1 affected FDR. We estimated FRR !
2.05 (95% CI, 1.96–2.14) for probands with !1 affected
FDR, similar to the meta-analysis FRR of 2.07 (95% CI,
1.89–2.26) that was adjusted to account for suspected
publication bias among source studies.11
Second-Degree Risk
The FRR estimates for constellations with 0 or 1
affected FDRs and increasing numbers of affected SDRs
are shown in Table 2. A positive second-degree family
history (in the absence of a positive first-degree family
history) can be associated with increased risk, but does
not appear to be of the same magnitude as a positive
first-degree family history. Second-degree family history
does appear to affect risk when combined with first-
degree family history. The FRR for 1 affected FDR with 1
affected SDR was 2.12 (95% CI, 1.90–2.35), significantly
higher than the FRR for 1 affected FDR and 0 affected
SDRs (FRR, 1.82; 95% CI, 1.72–1.93; P ! .007). The FRR
estimate for 1 FDR and !3 affected SDRs is even higher;
FRR was 3.37 (95% CI, 2.20–4.93) and in fact exceeds the
estimated FRR for 2 affected FDRs.
Third-Degree Risk
For those probands with no affected relatives
(FDRs, SDRs, TDRs) (N! 1,460,367), FRR was 0.83 (95%
CI, 0.81–0.86). Selected FRR estimates for constellations
with 0 or 1 affected FDRs and various combinations of
affected SDRs and TDRs are shown in Table 3. A positive
Table 3. Selected Familial Relative Risk (FRR) Estimates for
Probands With 0 or 1 Affected First-Degree
Relatives (FDRs) and Various Combinations of












probands FRR (95% CI)
0 0 0 1,470,367 0.83 (0.81–0.86)
0 0 !3 44,662 1.08 (0.97–1.20)
0 1 2 20,321 1.33 (1.13–1.55)
0 1 !3 13,858 1.21 (0.98–1.48)
0 2 !3 4061 1.48 (0.98–2.16)
0 !3 !3 2120 1.02 (0.41–2.09)
1 0 0 41,369 1.76 (1.63–1.89)
1 0 2 5560 1.90 (1.59–2.25)
1 0 !3 3255 2.01 (1.61–2.47)
1 1 0 8836 1.88 (1.59–2.20)
1 1 2 1882 2.50 (1.87–3.28)
1 1 !3 1357 3.28 (2.44–4.31)
1 2 0 1669 2.37 (1.58–3.43)
1 2 1 1006 1.98 (1.15–3.17)
1 2 2 523 2.70 (1.44–4.62)
1 2 !3 578 2.38 (1.19–4.26)
1 !3 0 453 2.79 (1.12–5.76)
1 !3 2 206 5.32 (2.14–10.96)
1 !3 !3 322 5.20 (2.24–10.24)
Table 4. Selected Familial Relative Risks (FRRs) for
Probands With Affected First-Degree Relatives
(FDRs) or Second-Degree Relatives (SDRs)
Diagnosed at Certain Ages
Proband
No. of
probands FRR (95% CI)
!1 affected FDR diagnosed %50 y
of age
6291 3.31 (2.79–3.89)
!1 affected FDR diagnosed between
50 and 59 y of age
12,094 2.53 (2.24–2.85)
!1 affected FDR diagnosed !50 y
of age
89,340 2.02 (1.93–2.11)
!1 affected FDR diagnosed between
60 and 69 y of age
25,084 2.22 (2.04–2.40)
!1 affected FDR diagnosed !60 y
of age
78,629 1.99 (1.90–2.09)
!1 affected FDR diagnosed between
70 and 79 y of age
32,445 1.97 (1.83–2.12)
!1 affected FDR diagnosed !70 y
of age
56,065 1.97 (1.86–2.08)
!1 affected SDR diagnosed %50 y
of age
19,616 1.84 (1.61–2.09)
Table 1. Selected Familial Relative Risk (FRR) Estimates for
Probands Considering Only First-Degree Relative
(FDR) Family History
No. of affected FDRs No. of probands FRR (95% CI)
0 2,232,396 0.89 (0.87–0.91)
1 87,089 1.91 (1.82–2.00)
!1 94,931 2.05 (1.96–2.14)
2 6966 3.01 (2.66–3.38)
3 762 4.43 (3.24–5.90)
4 92 7.74 (3.71–14.24)
!5 22 19.86 (7.29–43.24)
Table 2. Familial Relative Risk (FRR) Estimates for
Probands With 0 or 1 Affected First-Degree
Relatives (FDRs) and Increasing Numbers of






probands FRR (95% CI)
0 0 1,965,853 0.86 (0.84–0.88)
0 1 224,609 1.05 (0.99–1.11)
0 2 33,407 1.20 (1.05–1.38)
0 !3 8527 1.48 (1.11–1.93)
1 0 65,192 1.82 (1.72–1.93)
1 1 16,760 2.12 (1.90–2.35)
1 2 3776 2.31 (1.80–2.93)
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third-degree family history, in the absence of positive
first- and second-degree family histories, does not confer
a significant increased risk. For example, the FRR esti-
mate for probands with 0 affected FDRs, 0 affected
SDRs, and !3 affected TDRs was 1.08 (95% CI, 0.97–
1.20). However, in combination with positive first- and
second-degree family histories, third-degree family his-
tory can make a contribution to the total risk that is
significant. As an example, the FRR for probands with 1
affected FDR, 1 affected SDR, and 0 affected TDRs was
1.88 (95% CI, 1.59–2.20), increasing to a significantly
higher FRR of 3.28 (95% CI, 2.44–4.31) for probands
with 1 affected FDR, 1 affected SDR, and !3 affected
TDRs (P ! .004). In the absence of a positive second-
degree family history, presence of affected TDRs does not
appear to significantly change FRR (which is significantly
"1 for both constellations). For probands with 1 affected
FDR, 0 affected SDRs, and !3 affected TDRs, FRR was
2.01 (95% CI, 1.61–2.47) compared with FRR of 1.76 (95%
CI, 1.63–1.89) for probands with 1 affected FDR, 0 af-
fected SDRs, and 0 affected TDRs (P ! .125).
Age-Related Risk
Elevated FRR estimates based on the age of diag-
nosis of affected FDRs are shown in Table 4. Typically
disease onset%50 years is considered to be early for CRC,
but we analyzed ages at diagnosis of 60 and 70 years as
cutoffs as well. We estimated that for persons with !1
affected FDR diagnosed %50 years of age FRR was 3.31
(95% CI, 2.79–3.89); this is significantly higher than the
estimate for !1 affected FDR when the age of diagnosis
was !50 (FRR ! 2.02; 95% CI, 1.93–2.11; P % .001).
However, when the diagnosis age (of affected FDRs) was
limited to between 60 and 69 years of age, the FRR
estimate of 2.22 (95% CI, 2.04–2.40) was still elevated
above the chosen cutoff. In fact, it was significantly
higher (P ! .045) than the FRR for probands with !1
affected FDR when the age of diagnosis was not consid-
ered (FRR! 2.05; 95% CI, 1.96–2.14), although for coun-
seling purposes these numbers are not dissimilar.
When considering SDRs, age of diagnosis of the af-
fected relative also affects risk. The FRR estimate for !1
affected SDR (without respect to FDRs and TDRs) was
1.27 (95% CI, 1.22–1.33). The estimate for !1 affected
SDR diagnosed %50 years of age (FRR ! 1.84; 95% CI,
1.61–2.09) was significantly higher (P % .001).
Relationship Type- and Sex-Related Risks
We also estimated FRRs for specific FDR relation-
ship types, shown in Table 5. No difference was found
between FRRs for those with an affected parent versus an
affected sibling. Differences between FRRs estimated for
persons with affected brothers and sisters and for per-
sons with affected mothers and fathers were also not
significant. A statistically significant difference (of small
magnitude) was observed between female and male pro-
bands with !1 affected FDR, with such females having
FRR ! 2.12 (95% CI, 2.00–2.26) versus FRR ! 1.96 for
males (95% CI, 1.84–2.09; P! .04). Of particular interest,
and not previously published, was the risk estimate for
those with both an affected mother and an affected
father (FRR! 4.97; 95% CI, 2.72–8.34). This is increased,
although not quite significantly (P ! .07), over the FRR
for !2 affected FDRs when probands with both an af-
fected mother and father are excluded (FRR ! 3.21; 95%
CI, 2.87–3.58). This rather rare occurrence may represent
the situation of"1 predisposing genes segregating in the
offspring of the 2 affected parents. Therefore, we also
investigated FRRs for a pattern of family history involv-
ing cases on both sides of the family versus cases on one
side of the family only. To examine this issue, we com-
pared FRRs for probands with!2 affected SDR relatives,
separately for the case of !2 affected relatives on the
same side of the family and then for !1 affected relative
on each side of the family. We similarly made the com-
parison for probands with !2 affected TDRs, again sep-
arately for the case of !2 affected relatives on the same
side of the family and then for !1 affected TDR on each
side of the family. Results are shown in Supplementary
Table F. We excluded all probands with any affected
FDRs. In neither analysis was there any significant dif-
ference in the FRR estimates, whether the family history
was one-sided or both-sided.
Discussion
The purpose of this study was to define risk esti-
mates for CRC, based on family history data from a
homogeneous, well-characterized population, to better
assist physicians in determining CRC risk in their pa-
tients. We used a large genealogic and cancer registry
resource, the UPDB, to calculate FRRs for various con-
stellations of family history risk of CRC. Characteristics
of the Utah population represented in the UPDB data
include extended relationships, large family sizes, low
outmigration, low-to-normal inbreeding, and a genetic
composition similar to the US white population. Cancer
Table 5. Selected Familial Relative Risk (FRR) Estimates for
Probands With Various Affected First-Degree
Relationship Types as Well as Male and Female




probands FRR (95% CI)
!1 (parent) 31,619 1.96 (1.77–2.16)
!1 (sibling) 47,272 1.96 (1.86–2.07)
!1 (offspring) 18,644 3.06 (2.76–3.38)
Mother and father both affected 450 4.97 (2.72–8.34)
!2 (probands with both mother
and father affected excluded)
7392 3.21 (2.87–3.58)
!1 (male probands) 48,751 1.96 (1.84–2.09)
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records from the UCR, which are included in the UPDB
data set, strictly define the disease of interest. Because the
UPDB includes comprehensive statewide cancer records
from the UCR, it is free of ascertainment and recall bias
that might affect other studies that rely on interviews
with probands to assess cancer in relatives. This lack of
ascertainment bias is a particular strength of this re-
source.
Many previous studies have shown increased CRC risks
for relatives of affected persons. Although the more com-
mon FRR estimates such as !1 affected FDR that we
report here are consistent with studies included in the
meta-analysis of Butterworth et al,11 generally our esti-
mates are lower with tighter confidence intervals. These
differences may be due to the larger number of persons
included in our analysis and perhaps differences in the
incidence of disease between our population and those in
other studies. Utah has the lowest incidence of CRC in
the United States for both men and women, 47.5 and
35.2 per 100,000, respectively.1
In the meta-analysis of Butterworth et al11 sibling risk
(relative risk [RR] ! 2.79; 95% CI, 2.36–3.29) was re-
ported to be higher than parent-offspring risk (RR !
2.07; 95% CI, 1.83–2.34), and the authors suggested that
this may indicate the presence of recessive genetic factors
causing a susceptibility to CRC. We found no such dif-
ference between sibling and parent-offspring risk, even
though the numbers of probands with an affected parent
or affected sibling included in the analysis were "31,000
and "47,000, respectively. The Utah study’s population-
based approach avoids the challenges of combining stud-
ies with different methods and ascertainment bias as well
as accumulating higher numbers of patients for analysis,
thus making this study’s results more robust.
Although we were limited in our ability to explore
increased risk associated with whether !1 CRC predis-
position genes had an opportunity to segregate in a
pedigree, we only observed a clearly significant effect for
persons with both mother and father affected. Having
both an affected mother and affected father confers a
higher degree of risk (FRR ! 4.97; 95% CI, 2.72–8.34)
than having !2 affected FDRs (FRR ! 3.26; 95% CI,
2.92–3.63). Only a small number of probands had 2
affected parents (n ! 450), but this is an interesting
result that may be worth exploring in other large popu-
lation sets. The elevated FRR in persons with both par-
ents affected could result from gene–gene interaction,
gene–environment interaction, or a combination of both.
Our other FRR comparisons for second- and third-degree
family history from one side of the family versus from
both sides of the family did not show any significant
differences.
On the basis of the FRR estimate for having no af-
fected FDRs, SDRs, or TDRs (FRR ! 0.83; 95% CI,
0.81–0.86), persons with no known family history have a
mild but significant protection, as might be expected
(given that our overall risk estimates for all groups con-
sidered must average 1.0). Because this risk estimate relies
on information on current age of all FDRs, SDRs, and
TDRs (information which would not be typically avail-
able in a clinical setting), clinical recommendations for
persons with no known first-, second-, or third-degree
positive family history should include standard risk esti-
mates and screening recommendations based on their
current age.
Increased numbers of affected FDRs influence risk
much more than affected SDRs or TDRs. In fact, in the
absence of a positive first-degree family history (ie, 0
affected FDRs) and considering both affected SDRs and
TDRs (but not age of diagnosis in affected relatives) only
1 constellation had an FRR estimate that was signifi-
cantly "1.0 in the CI (0 affected FDRs, 1 affected SDR, 2
affected TDRs; FRR! 1.33, 95% CI, 1.13–1.55). However,
we previously noted that when combined with positive
first-degree family history, the presence of positive sec-
ond- and third-degree family history can significantly
increase risk.
Age at diagnosis of CRC in affected relatives contrib-
utes significantly to risk estimates. Although an age at
diagnosis %50 years typically has been used as a cutoff
for early onset, we have shown that even diagnosis be-
tween 60 and 69 years of age in affected FDRs increases
risk equivalent to the level of an affected FDR without
respect to age at diagnosis. Therefore, older age of onset
in an FDR should not be viewed as reassuring to the
patient. In addition, even the age of onset in SDRs (%50
years) can have an effect on the proband’s risk (FRR !
1.84; 95% CI, 1.61–2.09 versus FRR ! 1.27; 95% CI 1.22–
1.33 for !1 affected SDR without respect to age at
diagnosis).
Precisely how our findings can be applied to CRC
screening recommendations has yet to be determined,
but extrapolation from current guidelines appears to be
of some benefit. In the most current CRC screening
recommendations, family histories that represent a 2- to
3-fold increased risk (usually any FDR with CRC diag-
nosed at age "60 years) suggest that CRC screening, as
recommended for the general population, is indicat-
ed.29,30 Specifically, this includes any one of the screening
tools now used (annual fecal occult blood testing, sig-
moidoscopy every 5 years, combination of the first 2,
barium enema or computed tomographic colonography
every 5 years, or colonoscopy every 10 years). The only
difference in recommendations for persons with this level
of familial risk is that they should start at age 40 years,
rather than at age 50 years. This is because this group
exhibits the same risk at age 40 years as the general
population at age 50 years. Persons with a risk of!3-fold
compared with the general population because of family
history (included are those with an FDR diagnosed at age
%60 years or 2 FDRs with CRC) are now recommended
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starting at age 40 (or 10 years younger than the earliest
diagnosis in the family) and have repeat colonoscopy
every 5 years thereafter. Colonoscopy findings may alter
these recommendations.
In view of these widely accepted guidelines, we would
suggest provisionally that constellations of family risk
that result in approximately 2-fold increased risk or ap-
proximately !3-fold risk be screened accordingly. A brief
set of rules that specify constellations that meet these
criteria is presented in Table 6. Those persons with a
strong family history should always be considered for one
of the inherited syndromes of CRC. Physicians should
encourage persons with increased, but %2-fold, risk to be
screened according to guidelines for average risk.
This study has provided evidence that the existence of
affected extended relatives increases the risk of CRC in
probands. However, clinicians may question whether
many patients typically have valid family history infor-
mation for relatives more distant than first-degree and
whether the effort required to document and use this
information in clinical practice is cost- and time-effective.
With more people taking an interest in family history,
and a growing number of electronic tools and standards
for documenting and sharing family health histories, the
collection and clinical use of data from patients on fam-
ily health histories beyond the first-degree may be rea-
sonable in the near future.31,32
With regard to the limitations of the study, these
results may not be generalizable to other populations
with different racial or ethnic compositions. The Utah
population has been shown to be representative of the
US white and Northern European populations. Other
potential limitations include the reliance on appropriate
cancer diagnosis coding and inability to capture relatives
not represented in the UPDB genealogy or with cancer
diagnosed outside the state or outside the UCR time
period. We have not excluded persons from our analysis
with familial forms of CRC such as hereditary nonpol-
yposis colorectal cancer because they may not be reliably
identified; one may wonder if pedigrees containing per-
sons with these conditions have skewed the risk esti-
mates. However, in a previous UPDB study the number of
persons meeting the Amsterdam I criteria was estimated
to be small (65 of 9458 cases or 0.7% of the cases), and
none of these persons had a histology indicating familial
adenomatous polyposis syndrome.24 Finally, we ob-
served certain constellations in which the correspond-
ing FRR estimates did not follow the anticipated trend.
As an example from Table 3, FRR was 2.37 (95% CI,
1.58–3.43) for probands with 1 affected FDR, 2 af-
fected SDRs, and 0 affected TDRs. For those with 1
affected FDR, 2 affected SDRs, and 2 affected TDRs,
FRR was 2.70 (95% CI, 1.44–4.62). However, for pro-
bands with 1 affected FDR, 2 affected SDRs, and 1
affected TDR, FRR was 1.98 (95% CI, 1.15–3.17). Al-
though there is clearly a pattern of increasing FRR for
increasing numbers of affected relatives, individual
estimates were not always consistent with the trend,
and small sample size may be a factor.
Conclusion
In summary, this study is unique in providing
definitions of CRC risk based on first-, second-, and
third-degree family history constellations that have not
been reported previously. These risk estimates were based
on computerized genealogy and cancer registry data for
large numbers of persons from a well-defined population.
We have demonstrated that, although influencing risk to
a lesser extent than first-degree family history, positive
second- and third-degree family histories can have a sig-
nificant effect on a person’s risk of CRC. We have also
demonstrated how the age of cancer onset (estimated by
age at cancer diagnosis) in relatives affects risk. We have
provided a comprehensive set of supplemental tables that
accommodate various degrees of family history knowl-
edge, which can be used to more precisely define CRC
risk.
With respect to future work, producing absolute risk
calculations in real time from a person’s family history
constellation and current age based on the FRR estimates
presented could be automated. A computerized CRC
family history risk prediction tool could be created as
part of a personal health record application or as a
decision support component in an electronic health
record. Although family history is an important risk
factor for CRC, clinical, environmental, and behavioral
factors are also important, but how they affect genetic
susceptibility is uncertain. We are currently working to
create a more comprehensive CRC risk prediction model
based on a combined set of family history and clinical
data for a subset of the persons included in this current
study. It is hopeful that this will provide additional
Table 6. Family History Constellations That Will Produce
Approximately 2-Fold and Approximately !3-Fold
Familial Relative Risk Estimates
Approximately 2-fold risk Approximately !3-fold risk
1 affected FDR diagnosed
!50 y of age
or
1 affected FDR and 1 or
2 affected SDRs
!1 affected FDR diagnosed %50 y of
age
or
!1 affected FDR and !3 affected
SDRs
or
!2 affected FDRs (regardless of age
at diagnosis)
or




















March 2010 FAMILY HISTORY AND RISK FOR COLORECTAL CANCER 883
22
insight on the contributions of family history as well as
other factors on total CRC risk.
Supplementary Material
Note: To access the supplementary material
accompanying this article, visit the online version of
Gastroenterology at www.gastrojournal.org, and at doi:
10.1053/j.gastro.2009.11.044.
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3.1  Abstract 
 
Purpose:  To compare colonoscopy screening/surveillance rates by level of risk 
for colorectal cancer (CRC) based on age, personal history of adenomatous polyps or 
CRC, or family history of CRC.   
  Methods:  Participants were aged 30-90 years, were seen within 5 years at 
Intermountain Healthcare, and had family history in the Utah Population Database.  
Colonoscopy rates were measured for those with/without risk factors.   
  Results:  Among those aged 60-69, 48.4% had colonoscopy in the last 10 
years, with rates declining after age 70.  Percentages of those having had a 
colonoscopy in the last 10 years generally increased by risk level from 38.5% in those 
with a familial relative risk < 1.0 to 47.6% in those with a familial relative risk >3.0. 
Compared to those with no family history, the odds ratio for being screened 
according to guidelines was higher for those with 1 first-degree relative diagnosed 
with CRC ≥60 years or 2 affected second-degree relatives (1.54, 95% CI: 1.46-1.61) 
than those with 1 affected first-degree relative diagnosed <60 years or ≥2 affected 
first-degree relatives (1.25, 95% CI: 1.14-1.37).   
  Conclusions: Compliance with colonoscopy guidelines was higher for those 
with familial risk, but did not correspond with the degree of risk.  
 
3.2   Introduction 
Colorectal cancer (CRC) is the second leading cause of cancer-related death in 
the United States.  In 2010 it is estimated that 142,570 cases were diagnosed and 





a single affected first-degree relative essentially doubles an individual’s risk for the 
disease.2-5  Other important risk factors for CRC include age, with or without a 
personal history of CRC, adenomatous polyps or inflammatory bowel disease (IBD).1, 
6, 7  
  CRC is often preventable through screening because precancerous polyps can 
be identified and removed.8, 9  Findings from the National Polyp Study suggest that 
76-90% of CRC occurrences could be prevented through periodic colonoscopy.2, 10   
Updated screening and surveillance guidelines were published in 2008-2009 by the 
United States Preventive Services Task Force (USPSTF), the American College of 
Gastroenterology, the American Cancer Society, the Multi-Society Task Force on 
CRC, and the American College of Radiology (ACS–MSTF–ACR).8, 9, 11, 12  While 
current guidelines support the use of fecal occult blood testing (FOBT) or flexible 
sigmoidoscopy as screening options for those at average risk, colonoscopy is 
considered to be more sensitive.13-15   Consequently, guidelines recommend 
colonoscopy as the screening/surveillance tool for those with significantly elevated 
risk arising from a personal history of adenomatous polyps, surgically resected CRC, 
inflammatory bowel disease (IBD), or a family history of CRC.  Based on the 2003 
National Health Information Survey (NHIS), percentages of men and women 
reporting colonoscopy (32.2% and 29.8%, respectively) were higher than those 
reporting FOBT (16.1% and 15.3%, respectively) or sigmoidoscopy (7.6% and 5.9%, 
respectively).16  Current practice trends confirm that physicians most frequently 






  Screening guidelines recommend that average-risk individuals begin 
screening at 50 years of age.  According to data from the 2005 NHIS and the 2006 
Behavioral Risk Factor Surveillance System (BRFSS), between 50% and 60% of 
adults ≥50 years of age reported having had an FOBT in the past year and/or 
endoscopy (colonoscopy or sigmoidoscopy) in the past 10 years.18, 19  According to 
2008 BRFSS data for the state of Utah where this study was conducted, 67.2% of 
individuals aged ≥50 years report having ever had endoscopy versus 61.8% 
nationwide.20 
  Individuals who have undergone a surgical resection for CRC are at 
increased risk for a recurrence of CRC.  Current surveillance guidelines recommend 
colonoscopy to be performed 1 year after resection based on reports of a high 
incidence of apparently metachronous second cancers (i.e., originating separately 
from the original cancer) within 2 years after resection.21  It has been reported that 
between 55% and 61.2% of patients have had ≥1 colonoscopy or other complete colon 
examination within 18 months after resection, and between 52.4% and 73.6% have 
had ≥1 colonoscopy within 3 years after resection.22-25 
  For those with a family history of CRC or adenomatous polyps in first-degree 
relatives, it is recommended that screening start at age 40, or 10 years before the 
earliest age of diagnosis of a family member diagnosed with CRC, whichever is 
younger, with follow-up screening every 5 years.  Several studies have compared 
CRC screening rates (colonoscopy and/or FOBT) between persons with a positive 
family history and those without.26-31  In general, those with a positive family history 





recommendations compared to those without a family history.  But overall the 
prevalence of screening was found to be low, and the majorities of both groups had 
not been screened.  Limitations of these studies include small sample sizes, highly 
selected populations, self-reported family history, and most importantly, self-
reported CRC screening.  Only one study used an electronic medical record (EMR) 
for documentation of CRC screening.31  This study found that those with a positive 
family history were appropriately screened, based on risk-specific guidelines, less 
frequently than those with no family history of CRC.  This may be due to the fact 
that screening guidelines are more stringent for those with a family history than 
those at average risk.  Therefore compliance rates among those at increased risk are 
lower than those at average risk because more screenings are recommended in 
shorter time frames, meaning that there are more opportunities to be out of 
compliance. 
  We previously reported a comprehensive set of familial relative risk 
estimates based on 2.3 million individuals in Utah with various constellations of 
first-, second-, and third-degree relatives affected with CRC.4  These estimates were 
produced using the Utah Population Database (UPDB), a population-based resource 
with a computerized genealogy linked to statewide cancer registry records.  The 
UPDB was created in the early 1970s and contains genealogies for the original Utah 
pioneers (members of the Church of Jesus Christ of Latter-day Saints) and their 
modern-day descendants.32, 33  A high proportion of Utah residents (approximately 
60%) receive care through Intermountain Healthcare, an integrated healthcare 





resource and the linkage to Intermountain records have provided unprecedented 
opportunities for records-based research on cancer screening behavior in relation to 
family history of cancer. 
  The objective of this study was to compare colonoscopy screening/surveillance 
rates among those with various levels of risk based on family history and other 
factors, in a large sample using electronic family history and EMR data.  Using 
these risk factors linked to data on colonoscopy procedures performed, we measure 
the numbers in and out of compliance with adapted guidelines. 
 
3.3   Materials and methods 
The UPDB, described above, includes information for more than 7 million 
individuals, although not all have linked genealogical data. 4, 34  Cancer history 
information for these individuals is obtained from the Utah Cancer Registry (UCR; a 
National Cancer Institute Surveillance, Epidemiology, and End Results program 
registry since 1973) and death certificates.  A linkage has been created between the 
UPDB and clinical records from Intermountain Healthcare; 3.2 million individuals 
have records in both sources.   
  Intermountain Healthcare is a community-owned, nonprofit health care 
system that serves the health needs of Utah and southeastern Idaho residents.  
Intermountain electronically integrates data for all aspects of care, including 
inpatient and outpatient clinical and administrative data for diagnoses, procedures, 





  The Resource for Genetic Epidemiology (RGE) at the University of Utah 
governs access to the UPDB.35  RGE, University of Utah Institutional Review Board 
(IRB), and Intermountain Healthcare IRB approvals were obtained to conduct this 
research.   
  The individuals in this study were drawn from a pool of 357,208 CRC cases, 
matched controls (matched on age and sex), and relatives of cases and controls.  
Inclusion criteria for the current study were: (1) no record of death, (2) currently 
between the ages of 30 and 90, (3) part of ≥3 generations of Utah genealogy data and 
a descendant of original Utah pioneers, (4) seen as an inpatient or outpatient at 
Intermountain between December 2004 and December 2009, and (5) evidence of an 
Intermountain encounter 10 years previous to the most recent encounter.  The 
encounter criteria help to exclude individuals who are not current Intermountain 
patients and those who have not been patients in the system long enough to 
adequately assess screening/surveillance compliance.  
  The following data were collected for study individuals (data source in 
parentheses): Date of last colonoscopy (Intermountain inpatient and outpatient 
Current Procedural Terminology/Healthcare Common Procedure  Coding System  
and International Classification of Diseases 9 procedure codes [ICD-9]), diagnosis of 
CRC and surgical resection (Intermountain cancer registry), removal of an 
adenomatous polyp (contained in findings of pathology report), diagnosis of IBD 
(inpatient and outpatient ICD-9 codes and free text problem list entries), and dates 
of outpatient visits and inpatient hospital stays (Intermountain billing data).  





obtained from UPDB genealogy and UCR cancer data.  Among individuals with 
cancer recorded in the UCR, 94% link to ≥1 records in the UPDB and 64.2% have 
family information.  The type of relation and age at diagnosis of affected relatives 
were also collected from the UPDB.  The familial relative risk for each study 
individual was obtained by comparing their unique constellation of relatives affected 
with CRC, with familial relative risk estimates for various constellations previously 
published.4   An example of a family history constellation for a proband (considering 
CRC in the first- through third-degree relatives) is 0 affected first-degree relatives, 1 
affected second-degree relative, and 3 affected third-degree relatives.  Familial 
relative risk based on these extended constellations provides more quantitative and 
precise risk estimates than the guideline-based family history risk categories and is 
presented to provide an additional perspective on risk. 
While the total study population included individuals aged 30 to 90 years, we 
first evaluated the numbers of study individuals between 50 and 90 years of age who 
had evidence of colonoscopy in the past 10 years according to Intermountain data, 
stratified by age, risk factors, and also by familial relative risk level (e.g., <1.0, 1.0-
1.99, 2.0-2.99, >3.0).  These numbers are irrespective of how long individuals have 
had risk factors or whether colonoscopies were for screening, surveillance, 
diagnostic, or treatment purposes, due to the difficulty of distinguishing the reason 
for colonoscopy when using only coded data. 
  We also evaluated compliance with guidelines for those at normal risk or 
increased risk based on age, positive family history of CRC, a personal history of 





individuals aged 30-90 years with at least one risk factor were included.  We used 
adapted guideline criteria (Table 3.1) to assign each individual to a status of 
compliant or not compliant with risk factor-specific CRC screening (age, family 
history) or surveillance (polyps or surgically resected CRC) guidelines using 





Table 3.1: Adaptation of American Cancer Society, the Multi-Society Task Force on 
CRC, and the American College of Radiology (ACS–MSTF–ACR) joint 
screening/surveillance guidelines for early detection of colorectal adenomas and 








































ACS–MSTF–ACR for individuals at high or increased risk were simplified based on 
authors’ expert opinion in order to measure compliance in a practical way using 
available electronic sources of data.  Additional time periods beyond those specified 
in the guidelines were provided in order to count colonoscopies that occurred shortly 
after the due date.  For example, according to the guidelines those ≥50 years of age 
with no other risk factors are to be screened every 10 years.  Eleven years were 
provided in our adaptation of the guideline to measure compliance in order to allow 
capture of procedures occurring within the 10th year.  For those with a personal 
history of surgically resected CRC, only 1 year surveillance compliance (adapted as 
18 months) was measured because of the complexity of screening intervals past the 
first post-resection screening.  Due to surgical resection data being available 
electronically before colonoscopy dates were available, individuals with resections 
earlier than 1994 were not included in the analysis.  Compliance in those with IBD 
was also not assessed due to complexity; however, IBD diagnoses were used to 
exclude individuals from the group ≥50 years of age at “normal” risk (i.e., have no 
other risk factors considered in this analysis).  Multivariate logistic regression was 
used to quantify the relative odds that individuals with each particular risk factor 
would be compliant with guidelines through colonoscopy, compared with those at 













3.4   Results 
3.4.1   Colonoscopy within the last 10 years  
among those aged 50-90 
 
There were 71,446 individuals aged 50 to 90 years included in Table 3.2.  
Among other risk factors for CRC, 5836 (8.2%) had at least one adenoma 
documented and 2738 (3.8%) had a history of an advanced adenoma.  Individuals 
with advanced adenoma (defined here as multiple adenomas, villous adenoma, or 
high-grade dysplasia) are a subset of those identified with an adenoma.  Among 
those with ≥1 CRC affected first-degree relative, 8.7% had a first-degree relative 
diagnosed under the age of 50 years.  There were 55,646 (77.9%) considered at 
normal risk, having no CRC, IBD, or adenoma and having 0 CRC affected first-
degree relatives and ≤1 CRC affected second-degree relatives. 
  Evidence of colonoscopy in the last 10 years was found for 34.1% of 
individuals at normal risk and 57.8% of those with one or more risk factors.  By age 
group, the percentage of individuals with colonoscopy within 10 years was highest in 
the 60-69 year age range (48.4%), and lowest in the 80-90 age range (28.5%).  
Colonoscopy within the last 10 years was detected for most individuals with a 
history of CRC (65.7%), adenoma (83.9%), or advanced adenoma (93.9%).  Regardless 
of risk defined by familial relative risk, the 60-69 year age group remained the group 
with the highest colonoscopy rates. 
  We evaluated evidence of colonoscopy in the last 10 years in this same 





common risk category was familial relative risk < 1.0 (77.2%). There were 16.9% 
with a familial relative risk between 1.0 and 1.99, 4.6% with a familial relative risk  
          Table 3.2: Baseline characteristics for a sample of study individuals, aged  












Ages 50‐90  71,446 39.3  
      Ages 50‐59  25,374 39.0 1.00  (Reference)
      Ages 60‐69  17,877 48.4 1.46  1.41 – 1.52 
      Ages 70‐79  15,577 38.2 0.96  0.93 – 1.00
      Ages 80‐90  12,618 28.5 0.62  0.59 – 0.65
      Sex   
            Male  31,609 (44.2) 41.0 1.00  (Reference)
            Female  39,837 (55.8) 38.1 0.89  0.86 – 0.92
      History of CRC   
            No   70,673 (98.9) 39.1 1.00  (Reference)
            Yes  773 (1.1) 65.7 3.49  3.00 – 4.06
      History of adenoma   
            No   65,610 (91.8) 35.4 1.00  (Reference)
            Yes   5836 (8.2) 83.9 9.75  9.07 – 10.48
                   With 0 affected FDRs  4974 (85.2) 84.2 9.86  9.11 – 10.66
                   With ≥1 affected FDR  862 (14.8) 82.5 9.09  7.61 – 10.86
                          With 0 dx < age 50  775 (89.9) 82.1 8.89  7.38 – 10.71
                          With ≥1 dx < age 50  87 (10.1) 86.2 11.29  6.12 – 20.84
      History of advanced adenoma   
            No   68,708 (96.2) 37.2 1.00  (Reference)
            Yes  2738 (3.8) 93.9 26.40  22.54 – 30.91
                   With 0 affected FDRs  2311 (84.4) 94.5 29.14  24.35 – 34.87
                   With ≥1 affected FDR   427 (15.6) 90.9 17.31  12.43 – 24.10
                          With 0 dx < age 50   377 (88.3) 90.2 16.15  11.48 – 22.73
                          With ≥1 dx < age 50  50 (11.7) 96.0 38.41  9.31 – 158.42
     Affected FDRs   
           0 affected FDRs   64,159 (89.8) 38.6 1.00  (Reference)
          ≥1 affected FDR   7287 (10.2) 45.6 1.40  1.33 – 1.47
                 With ≥1 dx < age 50  632 (8.7) 48.9 1.53  1.31 – 1.79
                 With ≥1 dx age 50‐59  1155 (15.9) 50.6 1.64  1.46 – 1.84









15,800 (22.1)  57.8  2.74  2.64 – 2.84 





           
           
 
          Table 3.3. Sample of study individuals, aged 50-90, with  
                      evidence of colonoscopy in the last 10 years, according to  

























Based on a logistic regression model adjusted for age and sex,  
the trend in compliance with increasing FRR was significant  
at p < 0.001. 
 
 
between 2.0 and 2.99, and 1.3% with a familial relative risk ≥ 3.0. Colonoscopy rates 
generally increased by risk level, from 38.5% in those with a familial relative risk < 
1.0 to 47.6% in those with a familial relative risk ≥ 3.0. 
 
3.4.2    Screening/surveillance compliance rates  
using colonoscopy according  






We summarized colonoscopy screening compliance (Table 3.4) in a sample at 





Table 3.4. Colorectal cancer screening and surveillance compliance using colonoscopy according to risk-specific 
guidelines, and odds ratios for screening compliance through colonoscopy for individuals with CRC risk factors 









Normal risk *  55,646 35.0  1.00
CRC surgical resection **  529 40.1  1.27 1.06 – 1.53
Adenoma †  1273 58.4  2.57 2.29 – 2.89




degree relative diagnosis ‐ 10 years)  66  33.3     
Proband current age ≤ (earliest affected first‐
degree relative diagnosis ‐ 10 years)  237  NA¶     
















73,912 individuals ≥30 years of age with ≥1 risk factor were included in this 
analysis.  Among 55,646 considered at normal risk, 35.0% underwent colonoscopy 
within the last 11 years.  There were 529 with a history of a surgical resection for 
CRC ≥18 and ≤191 months ago and among these 40.1% had undergone colonoscopy 
within 18 months after the resection date.  Among 1273 individuals with a history of 
adenoma documented ≥6 years ago, 58.4% had colonoscopy within 6 years after 
polypectomy.  The higher set of criteria for increased risk based on a positive family 
history of CRC is “1 affected first-degree relative diagnosed <60 years or ≥2 first-
degree relatives of any age.”  For comparison with the view of risk presented in 
Table 3.3, individuals with ≥1 affected first-degree relative diagnosed <60 years of 
age would have a familial relative risk of 2.69 (95% CI: 2.43-2.96) and for those with 
2 first-degree relatives of any age the familial relative risk is 3.01 (95% CI: 2.66-
3.38).  In the 2518 individuals ≥40 years of age meeting the criteria, 38.6% were 
compliant with the guideline within the last 6 years.  For those younger than 40 
years of age who met the criteria, 33.3% underwent colonoscopy within the last 6 
years.  The lower set of criteria for increased risk based on family history of CRC is 
“1 affected first-degree relative diagnosed ≥60 years or 2 affected second-degree 
relatives.”  Once again, for comparison with Table 3.3, for those with ≥1 affected 
first-degree relative diagnosed ≥60 years the familial relative risk is 1.99 (95% CI: 
1.90-2.09) and for those with 2 affected second-degree relatives (in the absence of 
any affected first-degree relatives) the familial relative risk is 1.20 (95% CI: 1.05-
1.38).  Among the 9002 who met the increased risk criteria and who were also ≥40 





  We estimated the relative odds that individuals with a particular risk factor 
would be compliant with guidelines specific to their risk level, compared to 
compliance in those at normal risk with their appropriate guidelines, taking into 
account age and sex (Table 3.4).  The highest odds ratio was observed for those with 
a history of adenoma ≥6 years ago (2.57, 95% CI: 2.29-2.89) and the lowest was 
observed in those meeting the higher familial risk criteria (1 CRC affected first-
degree relative diagnosed <60 years or ≥2 first-degree relatives affected at any age; 
OR = 1.25, 95% CI: 1.14-1.37).  All groups at higher risk had significant 
improvement in screening/surveillance compared to the referent group. 
 
3.5   Discussion 
We report an analysis of colonoscopy rates in those with, and without, specific 
risk factors for CRC.  Colonoscopy rates in the last 10 years in a sample of 
individuals aged 50-90 years are reported (Table 3.2).  Almost half of individuals 
aged 60-69 had evidence of colonoscopy in the last 10 years, which is consistent with 
national self-reported screening behavior statistics.18, 19  Colonoscopy rates declined 
in those >70 years of age.  Comparisons between differences in 10-year colonoscopy 
rates in those with and without risk factors in Table 3.2 should be interpreted with 
caution as some colonoscopies may be for surveillance (in those with surgically 
resected CRC or adenoma), others for screening, and others as part of diagnostic or 
treatment processes.  Based on data presented in Table 3.3, it is clear that 
colonoscopy rates increase and then decline with age, peaking in the 60-69 age 





history have more frequent screening, compared to those with no familial risk.8, 11, 12  
Our analysis shows that while rates generally increase with familial relative risk 
level, indicating that a positive family history has some effect on screening behavior 
in this population, the increase does not reflect the increased frequency 
recommended by the guidelines.  For example, less than 40% of those with 1 affected 
first-degree relative diagnosed <60 years or ≥2 first-degree relatives any age had 
evidence of colonoscopy within the last 6 years.  In those with 1 affected first-degree 
relative diagnosed ≥60 years or 2 affected second-degree relatives the percentage 
with evidence of colonoscopy within the last 11 years was just over 40%.  Screening 
tests perform better in populations where the prior probability of having disease is 
higher.  It would be expected that failure to comply with screening guidelines in 
populations at increased risk would have a disproportionate negative effect on CRC 
prevention.  If higher priority were assigned to high risk individuals out of 
compliance with screening, the impact on prevention could be increased with a more 
efficient outlay of scarce resources. 
  Colonoscopy rates are reported for a sample of individuals aged 30-90 years 
according to risk factor-specific screening recommendations adapted from well-
accepted guidelines (Table 3.4).  The rate of colonoscopies within 18 months after 
CRC surgical resection (40.1%) and accompanying odds ratio for surveillance 
compliance compared to those at normal risk (1.27, 95% CI: 1.06-1.53) are lower 
than ideal.  However, some patients with stage III and IV CRC may not have further 
surveillance after resection because cancer care is a higher priority.  The colonoscopy 





ratio (2.57, 95% CI: 2.29-2.89) are higher but still leave room for improvement.  
Considering the influence of family history, the odds ratio for the lower level of 
familial risk (1.54, 95% CI: 1.46-1.61) is higher than the odds ratio for the higher 
level of risk (1.25, 95% CI: 1.14-1.37).  Based on a logistic regression model 
comparing the higher level of family risk to the lower family risk and adjusting for 
age and sex, p = 0.025.  This difference contradicts the assumption that those at 
higher risk would be screened more frequently.  The central finding that people at 
the highest levels of risk based on family history are not being screened according to 
the frequency specified by guidelines is particularly concerning.  Some studies have 
suggested increased compliance with family history is observed, yet in this large 
dataset the opposite is observed.  There does not appear to be a study design reason 
to explain this finding and we believe it may well be real and should have impact on 
how physicians and others view family history in gaining screening compliance. 
  At present there are no standardized system-wide efforts within 
Intermountain to obtain and analyze family history and communicate risk to 
providers or patients.  This lack of awareness of risk would interfere with 
appropriate application of risk-based screening guidelines.  At least one study has 
shown an inverse correlation between the number of affected relatives and the 
accurate documentation of family history in the medical record by the provider.36  
The implication is that a large family history requires more time to collect taking up 
an unacceptable amount of the visit.  Lastly, there may be a lack of provider 
awareness about the enhanced screening recommendations for those at high risk.  





the last 10 years in those with risk factors for CRC such as a previous diagnosis of 
CRC, adenoma, or a positive family history, were higher than those without these 
risk factors.  While colonoscopy rates in those with risk factors according to 
guidelines were higher compared to rates for those without the risk factors, efforts to 
improve compliance are still warranted.  
  An important limitation of this analysis is that we are unable to ascertain 
colonoscopies that were performed outside the Intermountain system, which may 
have led to underestimating screening rates by colonoscopy.  The study attempted to 
mitigate this by identifying individuals who had been seen in the system recently 
and who also had evidence of being long term users of the Intermountain system. 
However this does not guarantee that all colonoscopies were performed within the 
system.  Despite this limitation, the numbers of individuals in this study were 
sufficiently large that the results are nonetheless meaningful.  Although overall 
screening rates may have been improved by considering other screening tests such 
as FOBT or sigmoidoscopy, our analysis focused exclusively on colonoscopy, as is 
recommended by the majority of the guidelines we utilized.  Considering current 
practice trends, and the fact that those with the risk factors considered in this study 
are more likely to undergo this procedure for screening/surveillance than other tests 
such as FOBT, we believe this is justified.  In addition, we had concerns about 
completeness of FOBT and sigmoidoscopy data based on the fact that they are often 
performed in the outpatient setting and may not be as reliably documented 
electronically at Intermountain as colonoscopies.  As previously noted, it was 





for bias this would tend to overstate compliance rates with guidelines.  Screening 
and surveillance guidelines provide a recommendation for each risk factor 
separately and this is how compliance was measured.  Therefore, individuals with 
more than one risk factor (e.g., a family history of CRC and a personal history of the 
disease and resection) would be represented in more than one category in the 
analysis. Also, individuals with familial forms of the CRC such as Lynch Syndrome 
have not been excluded from our dataset because it is difficult to reliably identify 
them. In a previous UPDB study the number of individuals meeting the Amsterdam 
I criteria was estimated to be small (65 of 9458 cases or 0.7% of the cases), and none 
had a histology indicating familial adenomatous polyposis syndrome.37 
  This analysis of screening and surveillance behavior through colonoscopy 
addresses the limitations of similar studies including small sample sizes, highly 
selective populations, and self-reported family history and CRC screening.  The 
quality and depth of electronically available data on colonoscopy and risk factors, 
and particularly the integration of electronic family history data and cancer registry 
data in this study, are particular advantages contributing to this area of research.  
This study demonstrates the feasibility to use data from EMRs in 
combination with coded family history information to assess risk.  This has the 
potential to provide point-of-care clinical decision support and ‘just in time’ 
education to patients and providers.  Future efforts are being directed to create a 
CRC family history risk algorithm within a patient-entered family history tool 
deployed in our electronic patient portal.  Once deployed, this could allow 





individualized risk-based screening recommendations to both patients and 
providers, and the impact on compliance with recommended screening could be 
assessed. 
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How well does family history predict who will get
colorectal cancer? Implications for cancer screening
and counseling
David P. Taylor, MS1, Gregory J. Stoddard, MPH2, Randall W. Burt, MD3,4, Marc S. Williams, MD1,5,
Joyce A. Mitchell, PhD1, Peter J. Haug, MD1,6, and Lisa A. Cannon-Albright, PhD7,8
Purpose: Using a large, retrospective cohort from the Utah Population
Database, we assess how well family history predicts who will acquire
colorectal cancer during a 20-year period. Methods: Individuals were
selected between ages 35 and 80 with no prior record of colorectal
cancer diagnosis, as of the year 1985. Numbers of colorectal cancer-
affected relatives and diagnosis ages were collected. Familial relative
risk and absolute risk estimates were calculated. Colorectal cancer
diagnoses in the cohort were counted between years 1986 and 2005.
Cox regression and Harrell’s C were used to measure the discriminatory
power of resulting models. Results: A total of 431,153 individuals were
included with 5,334 colorectal cancer diagnoses. Familial relative risk
ranged from 0.83 to 12.39 and 20-year absolute risk from 0.002 to 0.21.
With familial relative risk as the only predictor, Harrell’s C  0.53 and
with age only, Harrell’s C  0.66. Familial relative risk combined with
age produced a Harrell’s C 0.67. Conclusion: Family history by itself
is not a strong predictor of exactly who will acquire colorectal cancer
within 20 years. However, stratiﬁcation of risk using absolute risk
probabilities may be more helpful in focusing screening on individuals
who are more likely to develop the disease. Genet Med 2011:xx(x):
000–000.
Key Words: colorectal cancer, family history, risk prediction, genetic
epidemiology, Utah Population Database
Colorectal cancer (CRC) is the second leading cause of deathamong cancers in the United States. In 2009, it was esti-
mated that 147,000 cases would be newly diagnosed and that
50,000 deaths would be caused by the disease.1 Because CRC
often develops from precancerous polyps that can be identiﬁed
and removed, it is one of the few cancers that can be prevented
through appropriate screening.2,3 It has been estimated that
more than half of deaths from CRC could be prevented through
early detection.4 Increased surveillance in those at elevated risk
may lead to the detection of more cases and, therefore, a
potentially greater mortality reduction than general surveillance
of the population.5 However, based on known risk factors,
predicting who will develop CRC is still a challenge.
Family history has often been cited as an important risk
factor for CRC based on evidence that those with a positive
family history for CRC have elevated risk compared with those
with no family history of the disease,6–9 and evidence that a
stronger family history results in even higher risks.10 The most
commonly used measure for family history of CRC is “1
affected ﬁrst-degree relative,” and in a recent, large, population-
based study, the associated familial relative risk was estimated
as 2.05 (95% conﬁdence interval: 1.96–2.14).10 Current screen-
ing guidelines are informed by these types of familial relative
risk studies and typically recommend that individuals with a
positive family history be screened earlier and more frequently
than those without.2,11,12 In addition, clinicians tend to rely on
familial relative risk estimates rather than other types of risk
representations such as absolute risk, even though absolute risk
may be more easily interpretable and understood.9,13,14
Although it has been established that a positive family his-
tory is associated with increased risk, an important question is
whether increased familial relative risk is actually a clinically
signiﬁcant predictor of who will develop CRC. There are few
published large prospective studies that assess familial risk and
subsequent CRC diagnosis. The studies that do exist rely on
self-reported family history and are limited to ﬁrst-degree rel-
atives.15,16 The primary purpose of this study is to assess how
well family history predicts who will get CRC over a period of
20 years, using a large, retrospective cohort from the Utah
Population Database (UPDB). Such information is critical for
health policy organizations that address screening strategies and
similarly important for practitioners who recommend screening,
and genetic counselors who advise persons of cancer risk.
MATERIALS AND METHODS
The UPDB is a population-based, electronic genealogical
resource that contains multiple linked data sources including
statewide cancer registry records.17 It was created in the early
1970s with data from the Utah Family History Library and
contains genealogies for the original Utah pioneers and their
modern day descendants.18,19 While the original Utah Geneal-
ogy included records for 1.6 million persons,17 today the UPDB
includes information for approximately 7 million persons, with
some pedigrees 11 generations deep, although not all persons
have linked genealogic data. The UPDB also includes a link to
the Utah Cancer Registry (UCR), a statewide cancer registry
established in 1966, which since 1973 has been part of the
Surveillance, Epidemiology, and End Results (SEER) network
of National Cancer Institute registries. Among those with cancer
in the UCR, 94% link to 1 records in the UPDB, and 64.2%
have family information. Cancer records are coded by disease
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site according to the International Classiﬁcation of Diseases of
Oncology.20 Information on site, stage, grade, age at diagnosis,
histology, and patient survival are included. The UCR only
reports independent primary cancers.
In contrast to many religious populations, individuals in the
UPDB have been shown to be genetically representative of US
white and northern European populations21–24 with a low-to-
normal level of inbreeding.25 Also, many are members of The
Church of Jesus Christ of Latter-day Saints, which has reli-
gious proscriptions against the use of coffee, tea, alcohol,
and tobacco. Consequently, much lower smoking rates may
play a role in Utah being among states with the lowest rates
of cancer.26
This project used a subset of UPDB records representing a
group of 2.3 million persons. These individuals were part of3
generations of Utah genealogy data and descendants of original
Utah pioneers. To protect the privacy of the study individuals,
identifying information was not available to the authors. The
Utah Resource for Genetic Epidemiology, created in 1982,
governs access to the UPDB.27 The Utah Resource for Genetic
Epidemiology and the University of Utah Institutional Review
Board granted approvals to conduct this research.
A retrospective cohort study design was used for this re-
search. Considering that the latest cancer diagnosis information
available in the dataset was from 2005, an observation period of
20 years was selected, with enrollment and family history
assessment determined for the year 1985. The following were
selection criteria: (1) individual’s record was available in the
UPDB before 1986, (2) no record of death before 1986, (3) no
record of CRC diagnosis before 1986, and (4) as of December
31, 1985, individual was between the ages of 35 and 80 years.
Data were collected on the individual’s age and family history
as of December 31, 1985. Numbers of CRC-affected ﬁrst-
degree relatives, second-degree relatives, and third-degree rel-
atives were gathered and numbers of CRC-affected ﬁrst-degree
relatives diagnosed between ages 50 and 69 years.
Previously, we reported familial relative risks for probands
with various combinations, or constellations, of affected rela-
tives with CRC, using the group of 2.3 million persons de-
scribed earlier.10 Examples of constellations and their corre-
sponding familial relative risks are listed in Table 1. A familial
relative risk for each proband in this study as of the assessment
date (December 31, 1985) was produced based on the proband’s
constellation of affected relatives in 1985.
During the observation period from 1986 to the end of 2005,
data were collected on the years of occurrence of CRC diag-
noses and deaths (from any cause) within the cohort. When an
individual was diagnosed with CRC or died during the obser-
vation period, their record was censored during the year the
event occurred. Cox regression was used to analyze the dataset,
with CRC diagnosis as the dependent variable. The concordance
statistic (or area under a receiver operating characteristic curve)
is often used to assess the discriminatory power of a prediction
model.28–31 Discriminatory power measures the ability of a
model to distinguish between those individuals having a partic-
ular outcome and others without the outcome. It corresponds to
the probability that a randomly selected individual who devel-
ops the disease has a higher predicted risk than that of a
Table 1 Examples of colorectal cancer (CRC) family history constellations and corresponding familial relative risk
estimatesa
No. affected ﬁrst-degree relatives No. affected second-degree relatives No. affected third-degree relatives Familial relative risk (95% CI)
0 0 0 0.83 (0.81–0.86)
0 0 3 1.08 (0.97–1.20)
0 1 2 1.33 (1.13–1.55)
1 0 0 1.76 (1.63–1.89)
1 0 3 2.01 (1.61–2.47)
1 1 0 1.88 (1.59–2.20)
1 1 3 3.28 (2.44–4.31)
2 0 0 2.96 (2.41–3.60)
2 0 3 4.82 (3.18–7.02)
2 1 1 1.80 (0.82–3.41)
2 1 3 4.67 (2.72–7.47)
3 0 0 2.96 (1.42–5.44)
3 0 1 4.21 (1.82–8.30)
3 0 3 9.63 (5.26–16.15)
3 1 0 12.39 (7.08–20.12)
1 (dx age 50 yr) NA NA 3.31 (2.79–3.89)
1 (dx age 50–59 yr) NA NA 2.53 (2.24–2.85)
1 (dx age 60–69 yr) NA NA 2.22 (2.04–2.40)
aFull estimates are reported in Ref. 10.
CI, conﬁdence interval.
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randomly selected individual who does not develop the disease.
The probability can range from 0.50, representing essentially a
coin toss, to 1.00, representing perfect discrimination. A con-
cordance statistic 0.70 is generally considered a threshold for
a potentially useful model, but a value 0.80 may be a more
reasonable level to provide adequate clinical utility.32
An equivalent of the concordance statistic for use with Cox
regression, Harrell’s C,33 was calculated for each model devel-
oped and compared. Because of the resource-intensive nature of
the Harrell’s C calculation, for models that included more than
100,000 individuals, Harrell’s C was averaged across 10 ran-
dom samples of 10% of the individuals in the model. Models
were developed for familial relative risk as the sole predictor,
age as the sole predictor, and familial relative risk and age
included together. Familial relative risk and age were modeled
as categorical variables.
As an alternative to using familial relative risk as the predic-
tor in a Cox regression, absolute risk was also used. For each
study individual, the absolute risk of developing CRC in the
next 20 years was estimated using the individual’s age and
familial relative risk in 1985, according to the method by
DuPont and Plummer.34 This method also requires age-adjusted
CRC morbidity rates and age-adjusted all-cause mortality rates
to estimate the absolute risk. These rates were created directly
from the UPDB population individually for the years 1981–
1985 and then averaged. The purpose was to simulate risk
estimates in 1985 as if it were a prospective study. Absolute risk
was also modeled using categorical variables. The expected
numbers of individuals to develop CRC within the observation
period among different levels of risk were estimated by sum-
ming the predicted absolute risk probabilities in each risk
category.
Subgroup analyses were also performed by dividing the
cohort into familial relative risk deciles, absolute risk deciles,
and age groups. For each, Cox regression was performed, and
Harrell’s C was calculated for the highest risk decile, or age
group, when compared with the lowest.
RESULTS
There were a total of 431,153 individuals included in the
cohort. Baseline characteristics of these individuals are listed in
Table 2, as well as numbers of CRC diagnoses. The range of
familial relative risk was 0.83–12.39. The majority of individ-
uals in this cohort (93.3%) had a familial relative risk 1.0.
Less than 0.4% had a familial relative risk 3.0. The range of
20-year absolute risk was 0.002–0.21, and the majority (57.4%)
had a probability between 0.01 and 0.03. More than 2% had a
20-year absolute risk probability0.03. During the observation
period, 5,334 individuals developed CRC. The age category
(measured at baseline) with the most CRC diagnoses was
60–69 (1,840/5,334  34.5%). The percentages of observed
CRC cases out of total individuals in each absolute risk category
ranged from 0.6% (0  absolute risk  0.01) to 25% (absolute
risk 0.13).
Table 3 contains results of Cox regression and Harrell’s C
analyses. When familial relative risk was the only predictor,
Harrell’s C  0.53. When age was the only predictor, the age
Table 2 Baseline characteristics and observed and expected CRC diagnoses for 20-yr observation period, 1985–2005
n (%) No. w/CRC in observation period (%) Expected no. CRC casesa
Total individuals 431,153 5,334 (1.2)
Age 35–49 yr 163,277 (37.8) 886 (0.5)
Age 50–59 yr 87,828 (20.4) 1,249 (1.4)
Age 60–69 yr 104,420 (24.2) 1,840 (1.8)
Age 70–80 yr 75,628 (17.5) 1,359 (1.8)
Familial relative risk
0  Familial relative risk  1.0 402,317 (93.3) 4,660 (1.2)
1.0  Familial relative risk  2.0 19,299 (4.5) 402 (2.1)
2.0  Familial relative risk  3.0 8,238 (1.9) 226 (2.7)
3.0  Familial relative risk  4.0 1,250 (0.3) 40 (3.2)
4.0  Familial relative risk  9.0 41 (0.1) 4 (9.8)
Familial relative risk  9.0 8 (0.1) 2 (25.0)
Twenty-year absolute risk prediction
0  Absolute risk  0.01 173,655 (40.3) 990 (0.6) 808
0.01  Absolute risk  0.03 247,438 (57.4) 3,991 (1.6) 3,822
0.03  Absolute risk  0.05 8,550 (2.0) 286 (3.3) 326
0.05  Absolute risk  0.07 1,465 (0.3) 61 (4.2) 83
0.07  Absolute risk  0.13 33 (0.1) 3 (9.1) 3
Absolute risk  0.13 12 (0.1) 3 (25.0) 2
aFrom absolute risk predictions based on 1981–1985 UPDB-speciﬁc incidence and mortality data.
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Table 3 Results of Cox regression to predict diagnosis of colorectal cancer (CRC) based on (a) familial relative risk, (b)
age, (c) familial relative risk and age, (d) absolute risk, (e) familial relative risk comparing the highest with lowest
decile, and (f) absolute risk comparing the highest with lowest decile
Hazard ratio (95% CI) Harrell’s C
Familial relative risk
0  Familial relative risk  1.0 Reference category 0.53
1.0  Familial relative risk  2.0 1.88 (1.70–2.08)
2.0  Familial relative risk  3.0 2.50 (2.19–2.86)
3.0  Familial relative risk  4.0 2.82 (2.06–3.85)
4.0  Familial relative risk  9.0 10.65 (4.00–28.40)
Familial relative risk  9.0 38.24 (9.56–152.94)
Age (yr)




Familial relative risk and age
0  Familial relative risk  1.0 Reference category 0.67
1.0  Familial relative risk  2.0 1.67 (1.51–1.85)
2.0  Familial relative risk  3.0 2.27 (1.98–2.59)
3.0  Familial relative risk  4.0 2.79 (2.04–3.81)
4.0  Familial relative risk  9.0 6.67 (2.50–17.77)
Familial relative risk  9.0 28.43 (7.11–113.73)
Age 35–49 yr Reference category
Age 50–59 yr 2.76 (2.54–3.01)
Age 60–69 yr 3.84 (3.54–4.16)
Age 70–80 yr 4.99 (4.58–5.44)
Absolute risk
0  Absolute risk  0.01 Reference category 0.64
0.01  Absolute risk  0.03 3.48 (3.25–3.74)
0.03  Absolute risk  0.05 7.64 (6.70–8.72)
0.05  Absolute risk  0.07 9.52 (7.35–12.33)
0.07  Absolute risk  0.13 21.85 (7.03–67.86)
Absolute risk  0.13 80.08 (25.78–248.73)
Familial relative risk (highest to lowest comparison)
Lowest decile (familial relative risk  0.83) Reference category 0.54
Highest decile (1.02  Familial relative risk  12.39) 2.17 (2.00–2.35)
Age (oldest to youngest comparison)
35–49 yr Reference category 0.69
70–80 yr 5.08 (4.66–5.53)
Absolute risk (highest to lowest comparison)
Lowest decile (0.002  absolute risk  0.003) Reference category 0.78
Highest decile (0.02  absolute risk  0.21) 12.21 (10.47–14.24)
CI, conﬁdence interval.
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group 35–49 years was used as the reference and Harrell’s C 
0.66. The age group with the highest hazard ratio was 70–80
(5.12, 95% conﬁdence interval: 4.70–5.57). Combining age and
familial relative risk as predictors produced a Harrell’s C 
0.67. Using absolute risk as the predictor, which is based on
age, familial relative risk, and population-speciﬁc CRC inci-
dence and all-cause mortality rates, produced a Harrell’s C 
0.64.
In the subgroup analysis, when the highest decile of familial
relative risk (1.02  familial relative risk  12.39) was com-
pared with the lowest (familial relative risk  0.83), Harrell’s
C  0.54. For age, comparing those in the 70–80 years age
group with those in the 35–49 years group, Harrell’s C  0.69.
Harrell’s C  0.78 for the analysis comparing the highest
absolute risk decile (0.02  absolute risk  0.21) with the
lowest (0.002  absolute risk  0.003). Harrell’s C statistic
estimates the probability that, of two randomly chosen patients,
the patient with the higher prognostic score will remain free of
CRC longer than the patient with the lower prognostic score
from the Cox regression model.33 That is, the model result and
the actual patient outcome were concordant, where the model
correctly discriminated, 78% of the time in this Cox regression
model.
DISCUSSION
We have described a retrospective cohort study that included
431,153 individuals aged 35–80 years at the beginning of the
20-year observation period. We are not aware of any other
retrospective cohort or prospective studies of family history and
CRC that have followed up this many individuals over this
length of time. In addition, family histories of CRC were
available electronically through a population-based electronic
medical data resource as opposed to typically self-reported data.
Numerous studies have demonstrated increased familial rel-
ative risk for CRC in those with affected relatives.9 According
to our analysis, however, family history as represented by a
familial relative risk estimate is by itself not a good predictor
(Harrell’s C  0.53) of exactly who will develop CRC in the
next 20 years. Even when comparing the highest familial rela-
tive risk decile in the cohort (1.02  familial relative risk 
12.39) with the lowest (familial relative risk  0.83), Harrell’s
C was 0.54. When familial relative risk cutoffs were set even
higher for the comparison, Harrell’s C continued to decline,
perhaps due to fewer numbers of cases. Familial relative risk is
commonly used to communicate risk levels in the literature and
among physicians and genetic counselors. However, with a
disease such as CRC, it may not be commonly understood that
although a familial relative risk estimate may be elevated, the
corresponding absolute risk may still not be high. For example,
hypothetically if a disease affects 10 of 1000 people with a
particular risk factor and affects 1 of 1000 people without the
risk factor, the relative risk is 10.0. Despite the seemingly large
relative risk, the absolute risk for those with the risk factor is
still only 10 of 1000 (1%).
In contrast to familial relative risk, age is a stronger predictor
for CRC (Harrell’s C 0.66). Including familial relative risk in
addition to age only improves the discriminatory power by 0.01,
to 0.67. Absolute risk, which combines both familial relative
risk and age, produced a Harrell’s C  0.64. Considering
absolute risk uses the same variables and takes into account
population-speciﬁc CRC incidence rates; it is not clear why this
statistic was not higher. In the age subgroup analysis comparing
those in the 70–80 years age group with those in the 35–49
years group, Harrell’s C  0.69. These ﬁndings illustrate that
using familial relative risk in combination with age, or alterna-
tively absolute risk, has moderate predictive value for CRC.
However, in the absolute risk subgroup analysis where the
highest decile was compared with the lowest, Harrell’s C im-
proved substantially to 0.78. Although one may question the
clinical utility of this particular subanalysis, it is worth noting
that the highest decile of absolute risk includes those with a
20-year risk of 0.02 and greater. For illustration, 0.02 is essen-
tially the 20-year risk of a 50-year old with 1 CRC affected
ﬁrst-degree relative, so the highest decile of absolute risk in-
cludes more than just those at the extreme high end of risk based
on family history.
To provide additional perspective on the levels of Harrell’s C
found in this study based on family history or family history in
combination with age, a recent comprehensive risk prediction
model for CRC that included a range of risk factors including
family history produced a concordance statistic of 0.61.28 This
was based on validation in a population independent of the one
used to build the model.
Despite the moderate Harrell’s C value of models taking into
account family history and age, the potential clinical value of a
predictive model based solely on these risk factors is doubtful.
However, it may be useful to consider aspects of the analyses
presented in Tables 2 and 4 for decisions about appropriate
screening. At the very highest levels of risk (familial relative
risk  4.0 or absolute risk  0.07), relatively large percentages
of individuals (e.g., 1 in 4 or 1 in 10) categorized by both
familial relative risk and absolute risk end up developing CRC.
However, at more moderate levels of risk, absolute risk tends to
stratify individuals more appropriately. As an example, there
were 4,660 CRC cases among 402,317 individuals with familial
relative risk 1.0 (1.2%). Absolute risk roughly divides the
same number of individuals into two categories, absolute risk
0.01 and 0.01  absolute risk  0.03, where 3,991 cases were
classiﬁed among 247,438 individuals (1.6%) in the latter cate-
gory. In the former category, at the lowest level of absolute risk,
there were 990 cases out of 173,655 individuals (0.6%). At
higher levels of risk, there were 272 CRC cases that developed
in 9,537 individuals with familial relative risk 2.0 (2.9%).
There were 353 cases that developed in the 10,060 with absolute
risk 0.03 (3.5%). Absolute risk also has the beneﬁt of facili-
tating the prediction of expected numbers of cases, and based on
expected numbers of CRC cases in Table 2, it predicts fairly
well how many individuals in each risk category are going to
develop the disease in a 20-year time period.
This method of using absolute risk, based on age and family
history, may be a reasonable way to quantify and stratify CRC
risk, and these results demonstrate the possible utility. Particu-
larly in the higher absolute risk categories, the numbers of
cancers or precancers discovered through screening could po-
tentially be much higher than in the general population. Con-
sidering the costs of screening, particularly colonoscopy, there
are ﬁnancial beneﬁts in targeting and screening a smaller seg-
ment of the population and detecting a greater number of
potential cases. It may also be easier to motivate those who are
at increased risk to undergo screening, especially using more
understandable absolute risk probabilities. In addition, the po-
tential yield by percentage of appropriate screening increases as
risk level increases.
Additional insights from absolute risk estimates may be
gained from Table 4, which presents an adaptation of National
Comprehensive Cancer Network (NCCN) screening guidelines
for those with a positive family history of CRC.35 Twenty-year
absolute risk estimates are provided for 5-year age increments
from 35 to 80 years according to notable family history patterns
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and for those at average risk (deﬁned as having a familial
relative risk of 1.0). NCCN colonoscopy recommendations for
each family history category are noted as well. One may con-
sider the absolute risk of a 50-year old with average familial
relative risk as estimated from our dataset (20-year absolute
risk 0.01) as a reference point. Generally, there is consistency
between the NCCN recommendations and the absolute risk
patterns in that the most aggressive screening recommendations
are associated with the highest levels of absolute risk. However,
increased screening based on affected second-degree relatives
may not be justiﬁed based on these data.
Although the absolute risk estimates in this research are
based on familial relative risks that consider extended CRC-
affected relatives (second- and third-degree relatives) in addi-
tion to affected ﬁrst-degree relatives, our previous work has
shown that the inﬂuence of extended relatives is relatively
small; risk estimates are available that consider only ﬁrst-degree
relatives.10 Because patients often are not aware of the cancer
history (or get it wrong) in their extended relatives, this may be
important to consider.36 In addition, considering the limited
time clinicians have to obtain family history, not having to
collect data on second-degree relatives would be beneﬁcial to
some degree. Further research could address the impact of
limiting the familial relative risk estimates to only affected
ﬁrst-degree relatives in the absolute risk estimates and in the
expected/observed numbers of cases by risk category.
The limitations of this study include the fact that we were
unable to determine whether some individuals moved out of
state during the 20-year observation period and, therefore,
should have been censored for analysis; this limitation would
have served only to lower our estimates of diagnosis rates from
truly higher rates and does not change our conclusions. Similar
to other UPDB-based studies,10 these results are generalizable
to other populations of northern European origin but may not be
generalizable to populations with very different racial and eth-
nic compositions. There is a reliance on appropriate cancer
coding, but the source of cancer data was a National Cancer
Institute’s Surveillance, Epidemiology, and End Results regis-
try. Not all relatives of individuals may be represented in the
UPDB genealogy, but we anticipate no bias in such represen-
tation. In addition, the incidence of CRC in Utah is the lowest
in the United States.37 Although CRC incidence rates are
slightly different in men and women and also between sites
(e.g., colon versus rectum), we did not distinguish by sex or by
site in this study, consistent with the level of granularity of the
previously generated familial relative risk estimates. It is also
not known what screening may have occurred in the cohort,
particularly in those at increased familial risk, and what effect
this may have had in preventing CRC that would have otherwise
occurred. This remains a possible minimal confounding factor
based on observations in a yet to be published parallel study.
Also, individuals with familial forms of CRC such as hereditary
nonpolyposis CRC have not been excluded from this study
because they may not be reliably identiﬁed and one may ques-
tion whether this could skew the analysis. However, based on a
previous study using individuals in the UPDB, only a small
number met the Amsterdam I criteria (65 of 9458 cases or 0.7%
of the cases), and none had a histology indicating familial
adenomatous polyposis syndrome.38 Despite the limitations
identiﬁed, this study adds considerable deﬁnition and speciﬁcs
as to how the relative risks, which to date have been used to
establish screening strategies for those with a family history of
this disease, actually play out over a 20-year period. These
results should be carefully considered by health policy organi-
zation as they establish screening guidelines and by clinicians
and genetic counselors as they deal with persons and families
with familial colon cancer risk.
In conclusion, although previous studies have demonstrated
increased relative risk among those with a family history of
CRC, this large retrospective cohort study has demonstrated that
Table 4 Twenty-year absolute risk estimates by age and history of CRC-affected first- and second-degree relatives
(FDRs and SDRs)












SDRs dx any age
35 0.002 0.006 0.008 0.005 0.007 0.003
40 0.004 0.011 0.015 0.009 0.013 0.005
45 0.007 0.018 0.023 0.014 0.021 0.009
50 0.010 0.026 0.034 0.021 0.031 0.013
55 0.014 0.036 0.046 0.028 0.042 0.017
60 0.018 0.045 0.059 0.036 0.054 0.022
65 0.021 0.052 0.067 0.041 0.061 0.025
70 0.021 0.052 0.067 0.041 0.061 0.025
75 0.018 0.045 0.058 0.035 0.053 0.021
80 0.013 0.032 0.042 0.025 0.038 0.015
Colonoscopy
recommendationa
Every 10 yr starting
at age 50 yr
Every 5 yr starting
at age 40 yr
Every 3–5 yr starting
at age 40 or 10 yr
before the earliest
CRC dx
Every 5 yr starting
at age 50 yr
Every 3–5 yr starting
at age 40 or 10 yr
before the earliest
CRC dx
Every 5 yr starting
at age 50 yr
aAdapted with permission from The NCCN 3.2010 Colon Cancer Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network, 2010. Available
at: http://www.nccn.org. Accessed September 3, 2010. Most recent and complete version of the guideline is available at www.nccn.org.
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family history, without respect to age, is not a strong predictor
of exactly which individuals will acquire CRC in the next 20
years, based on Cox regression and a measurement of concor-
dance. It is important to keep in mind that even if a relative risk
estimate may seem large, absolute risk may still be small if the
incidence of a disease is low. When combined with age in an
absolute risk estimate, family history does seem to improve
concordance in a subgroup analysis to compare those at higher
risk with those at very low risk. However, it is doubtful that a
clinically useful statistical model for predicting who will ac-
quire CRC at an individual level can be produced using just age
and family history. Despite this, absolute risk predicts fairly
well how many individuals in particular risk categories will
develop the disease over a period of 20 years. Stratiﬁcation of
risk using absolute risk in a clinical setting could help target
screening on those individuals who are more likely to develop
the disease. Future work would include validating these abso-
lute risk estimates in an independent population, performing a
cost/beneﬁt analysis to determine optimal screening recommen-
dations based on risk levels, and providing a web-based tool for
clinicians to estimate absolute risk based on a patient’s current
age and family history.
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             In this research we explored the role of family history in CRC using a 
combination of unique data resources.  In this section of the dissertation the 
principal findings of each phase of the research will be presented.  Insights that 
were gained in the process and future directions for research in this area will also be 
discussed.  
 
5.1  Family-history-based constellation risk for CRC 
 
The first phase of research explored family history-based risk for CRC in 
more depth than has been published to date, by not only examining the contribution 
of CRC-affected first-degree relatives, but from constellations of affected relatives 
from the first, second, and third degrees.  We measured risk in a population of more 
than 2.3 million individuals with electronically available family history and cancer 
history data, and provided very precise individual risk estimates based on an 
individual’s specific “constellation” of affected relatives.  We hypothesized that the 
influence of extended relatives’ CRC histories might have a substantial impact on 
risk to a proband, an effect that may have been missed in other studies that 





accurate extended family histories.  This study confirmed the role that affected first-
degree relatives play in risk.  For individuals with ≥1 affected first-degree relative, 
the relative risk was 2.05 (95% CI, 1.96 –2.14), which was consistent with previously 
published estimates.  Our estimates were generally slightly lower than other similar 
published estimates and had tighter confidence intervals, which may be due to the 
large numbers of individuals in our study as well as lower rates of cancer in the 
state.  However, when there was no positive first-degree history and risk was only 
estimated considering the second and third degrees, we did not find a substantial 
increase in risk compared to those at average risk (RR = 1.0).  (As a reminder, we 
considered a two-fold increase in risk or a relative risk of 2.0 to be a convenient 
cutoff for a “substantial” or “clinically significant” increase in risk.)  When combined 
with a positive first-degree family history, however, the influence of affected 
extended relatives can increase risk to a degree that may be clinically significant for 
certain constellations.  In general though, this research confirmed the conventional 
wisdom that first-degree relatives are the most important to consider in clinical 
assessments of family history for CRC risk evaluation. 
Other findings from this phase of the research were that when a proband’s 
mother and father are both affected with CRC, risk is much higher (FRR=4.97; 95% 
CI: 2.72-8.34) than in those with ≥ any other 2 affected first-degree relatives 
(FRR=3.21; 95% CI,2.87–3.58).  While the difference is not quite statistically 
significant at the 0.05 level (p = 0.07), it is an interesting finding that has not been 
previously published and could result from gene–gene interaction, gene–





although an age at diagnosis <50 years typically has been used as a cutoff for early 
onset, even diagnosis between 60 and 69 years of age in affected first-degree 
relatives increases risk to a degree that is clinically significant and perhaps has not 
been highlighted before.  One of the most useful aspects of this research may have 
been the comprehensive set of relative risk estimates for constellations of affected 
family members from the first to the third degree that were produced.  We also 
provided estimates for different levels of known family history (e.g., just first degree 
or first and second degree) to accommodate clinicians with varying levels of 
knowledge of a patient’s family history.  This first phase of the research provided a 
solid foundation for the other two phases in the project and also makes a 
contribution to the literature concerning family history-based risk for CRC. 
 
5.2  Screening and surveillance compliance  
through colonoscopy in those at  
increased risk for CRC 
 
In this second phase of research we combined data from the UPDB and 
Intermountain Healthcare to compare colonoscopy screening and surveillance rates 
by level of risk for CRC based on age, personal history of adenomatous polyps or 
CRC, and family history of CRC.  Common guidelines for those at increased risk 
based on these risk factors were adapted to set standards for appropriate screening 
frequency.  Previous studies have compared screening rates in those with, and 
without, a positive family history, but the sample sizes were generally low, highly 





improved on each of these limitations, making use of the recently created linkage 
between the UPDB and Intermountain Healthcare data. 
 We found that colonoscopy rates generally increase with familial relative risk 
level, which indicates that a positive family history tends to have some effect on 
screening behavior.  However, according to recommended guidelines, there is still 
much room for improvement in how frequently those at increased risk (as well as 
those at average risk) are screened based on their family history.  This finding also 
applies to those at increased risk based on a history of adenoma or personal history 
of CRC.  An important limitation of this study is that we were not able to measure 
colonoscopies that occurred outside the Intermountain system, which could have led 
to underestimation of the rates.  A study such as this was not necessary to recognize 
that screening rates are not at recommended levels, even in those at increased risk.  
However, this study was unique in being able to quantify these rates in such a large 
population with electronically available family history, colonoscopy, adenoma, and 
surgically resected CRC data.  It may help other researchers to explore innovative 
uses of combined data resources such as these.  In the ideal research world a patient 
would receive care in a single-payer, single healthcare network where a record of all 
health events and interactions with the system would be electronically documented 
in a structured and coded fashion.  In the real world where patients have 
interactions with multiple health networks and data are stored in various formats 
and levels of structure, it would still be worthwhile to integrate records across 
systems.  With the rise of health information exchanges and projects such as the 





informatics infrastructure for the Center for Clinical and Translational Science at 
the University of Utah, this is becoming more and more of a reality.  
 
5.3  How well does family history predict  
who will get colorectal cancer? 
 
The final phase of the research intended to explore the value of family history 
in clinical practice through a retrospective cohort study to determine how well 
knowing a patient’s risk at a point in time helps predict whether they will develop 
CRC in the next 20 years.  This retrospective study design is essentially the same as 
a prospective study leading some to characterize these types of studies as “pseudo-
prospective” trials.  Few prospective studies have been reported for family history’s 
role in CRC, and those that exist have small sample sizes and self-reported family 
history data.  No retrospective cohort study has been published in this area. This 
study, following more than 430,000 individuals over 20 years, is just one of many 
examples of how the UPDB can facilitate research that could not be conducted in 
many, if any, other places in the world. 
The main finding of this study was that family history, by itself, is not a 
strong predictor of exactly who will develop CRC within 20 years.  Despite the 
elevated relative risk estimates found in the first phase of the project and in the 
literature, this result was not surprising based on the fact that CRC is a relatively 
rare disease.  In order for a risk factor to have strong predictive value by itself, it 
would need to produce relative risk estimates many times greater than what we 
found.  Absolute risk, although not mentioned in the literature as frequently, is 





smaller and perhaps less impressive than relative risk estimates, which may be 
factors in why they are not as commonly used. 
Although overall family history did not appear to have strong predictive 
value at the individual level, in those at the highest levels of risk it has the 
capability to predict the percentage of individuals among particular risk categories 
who will develop the disease.  In other words, stratification using a tool like absolute 
risk can identify those who are at very high risk, and a good percentage of those at 
very high risk end up developing the disease.  Focusing screening efforts in those at 
higher levels of risk, for instance based on absolute risk stratification, would result 
in detecting more cases than uniform screening in the entire general population. 
In comparing screening guidelines from the National Comprehensive Cancer 
Network for those with a positive family history of CRC, we found consistency in the 
guidelines with absolute risk patterns we observed; the most aggressive screening 
recommendations are associated with the highest levels of absolute risk. 
Our conclusions were that it is unlikely that a clinically useful model can be 
created to predict who will develop CRC at an individual level, with a reasonable 
degree of accuracy, using just family history and age.  However, absolute risk 
predicts fairly well the numbers of individuals in certain risk categories that will 
develop the disease over a 20-year period.  Using estimates such as these in a 
clinical setting could help identify those who are more likely to develop the disease, 







5.4 Additional insights and lessons learned 
 
In addition to the findings already presented there were other insights 
gained from this research that may be beneficial for those exploring similar paths.  
First, the data resources available in Utah are incredibly unique.  There are few 
places with so much clinical, family history, and cancer registry data available 
electronically for research.  Ties between the UPDB and health care institutions 
such as Intermountain Healthcare and the University of Utah Health Sciences 
Center facilitate rich research opportunities. Luckily projects such as FuRTHER will 
help to tie these unique data resources even more closely together to facilitate more 
advanced research and requiring less administrative overhead. 
While the data resources allowed us to explore interesting questions posed in 
this research, it is difficult to predict risk in cancer.  The known risk factors are 
generally not strong enough for accurate prediction in typical clinical practice.  It is 
interesting to note that other risk prediction models with very modest predictive 
values (e.g., AUC = 0.60) are commonly used in clinical practice for risk prediction.  
They may have their places in clinical practice, but many may not be aware that 
their predictive value is so limited. 
While family history has been cited as one of the most important risk factors 
for CRC, on an absolute scale, it is still not a strong predictor.  However, as 
previously described, even though it is not a strong predictor overall, family history 
still appears to have some value in stratifying those at risk.  Better tools to collect 
and make use of family history in a clinical setting should be explored for CRC and 





Although clinical data resources in the state, such as those at Intermountain 
Healthcare, are some of the most complete in the nation, using EMR data in a 
research project such as this can be challenging.  Although many of the challenges 
were known at the beginning of the project, their extent was not fully appreciated.  
An important objective early in the project was to build a comprehensive risk model 
for CRC that not only utilized family history data, but other risk factors based on 
Intermountain clinical and administrative data.  We believed that a matched case-
control design was most appropriate, based on previous UPDB research involving 
family history.  In addition, we approached the development of a risk model from the 
perspective of the data mining/machine learning world more than from 
epidemiology.  However, we found these techniques from machine learning 
inadequate to deal with certain issues, for instance to appropriately handle data 
based on a matched case-control design. 
The problems continued and deepened.  In the initial comprehensive model 
study design we did not select controls with appropriately matched exposure 
windows.  After going through the labor to collect and analyze data, we realized we 
had some made some “textbook” epidemiological study design errors.  With the 
proper help of an epidemiologist we created a modified case-control study design.  
Even with the modified study design we encountered a number of challenges.  It is 
very easy to make study design mistakes that will cause bias or produce unreliable 
results in the analysis.  Considering that we were selecting Intermountain patients 
as controls (seen as either inpatients or outpatients), rather than selecting them 





selected controls are actually sicker than those individuals in the general 
community. 
These issues highlighted the need for proper epidemiological and statistical 
assistance in the early planning stages of the project.  In retrospect it seems simple, 
but research objectives evolve and finding assistance that is well-matched to 
accomplish these objectives can be challenging.  Opportunities are becoming 
increasingly common because of the availability of data resources and conducting 
this type of research effectively is facilitated by collaboration between those with 
expertise in fields such as biomedical informatics, epidemiology, and statistics.  How 
to effectively build cross-functional teams to answer research questions such as 
these may be a worthwhile area for future exploration.  
Perhaps the most significant problem we encountered, which was a factor 
that produced such a complicated study design, was the issue of missing clinical 
data.  Although Intermountain has a longer history of electronically captured data 
than most institutions in the US, data were not reliably available before 2001 for the 
risk factors considered.  There were certain data elements available long before that, 
but not being able to measure all the relevant risk factors reliably for the same 
period of time caused difficulty. Other problems included multiple sources of the 
same basic data that were not always in sync, multiple master patient identifiers for 
the same patient, and missing or erroneous clinical data.  Also, it was difficult to 
determine if certain data were missing, for example, because the patient did not 
have a particular condition in the past, or simply because it was just not documented 





amount of care in the state, but it was impossible to determine if a patient had care 
provided outside the system and therefore documentation might be missing.  Some 
of the known risk factors for CRC are just not available as part of EMR data (e.g., 
red meat consumption), are not documented reliably (e.g., alcohol use), or are not 
contained in structured data that we could easily collect.  With regard to 
medications, it was impossible based on the data available to determine if a patient 
filled a prescription, let alone actually took the medication.   
At the most basic level, we could not determine the lifetime exposure for the 
risk factors, or even for a reasonable period of time, based on the EMR data.  
Although considerable time was spent in trying to address these issues and make 
the best of the situation, the problems halted this track of the research.  EMR data 
may be useful depending on the research question, but for many studies there are 
substantial limitations.  Understanding the limitations of the data and working with 
individuals who have deep experience in study design to mitigate or work around 
them is essential. 
Another lesson learned was that how risk is communicated is important. The 
literature around risk factors in CRC focuses on relative risk, which is not as 
intuitive as methods such as absolute risk.  As previously described, relative risk 
may appear to be elevated based on a particular risk factor but because of the 
overall low incidence of a disease, the actual risk (as reflected by absolute risk—a 
probability over a defined period of time) may still be low.  While these limitations of 
relative risk are documented, it appears that even among researchers and clinicians, 





5.5 Relevance for biomedical informatics 
 
The Department of Biomedical Informatics at the University of Utah has 
three academic tracks: (1) Clinical research and translational informatics, (2) Health 
care/clinical informatics, and (3) Public health informatics.  This research project 
has helped advance the field of biomedical informatics in each of these areas. First, 
with respect to clinical research and translational informatics, we extended genetic 
epidemiological tools and techniques to measure risk more comprehensively and 
with more granularity than reported in the past. We explored how disparate data 
resources (both clinical- and research-oriented) could be combined to answer 
clinically-relevant questions.  This involved investigating the quality of clinical data 
resources for a secondary research use as well. We also explored the feasibility of 
machine learning techniques in disease risk prediction. 
In the health care/clinical informatics area, this research provides 
foundational knowledge for other risk prediction-related projects involving clinical 
decision support, human-computer interaction, patient portals and personal health 
records, and ambulatory EMR order entry.  It particularly raises the question of how 
risk factors can be better captured as part of an electronic health record, particularly 
through more direct patient involvement. 
Last, in public health informatics we conducted a population-based 
retrospective cohort study to measure whether a risk factor was clinically 
significant, which was a novel use of the data resource. We also applied absolute risk 
on a population level to predict how many individuals at certain levels of risk will 





biomedical informatics through the innovative application of tools and techniques on 
unique data resources to explore risk for disease. 
 
5.6 Future directions  
 
It has been noted that a unique set of data resources are available in Utah, 
without which this research would not have been possible.  However, the UPDB has 
strict guidelines around appropriate uses of the data.  Although it would be feasible 
to identify individuals or families at increased risk for a disease such as CRC based 
on risk estimates based on UPDB family history and cancer data, contacting these 
individuals (i.e., using the data for clinical care purposes) is prohibited.  Therefore, 
other methods must be explored for capturing and utilizing family history data in 
clinical practice.  In actuality, according to HIPAA, a physician may disclose family 
history information about a patient to another health care provider for the purpose 
of treating another patient (e.g., a family member).  In a health system such as 
Intermountain Healthcare where many patients may be related, one might foresee 
an opportunity to collect family history relationships and hopefully with the 
patient’s consent, use that information and existing medical records to build a 
network of family health histories that could be used in clinical care. 
In addition, several other opportunities have been identified for future 
research.  One would be to validate the absolute risk estimates produced in the third 
phase of the project in an independent population to determine whether our 
techniques are sound and how well the Utah population compares to other 





perform a cost/benefit analysis using our findings on risk levels to determine optimal 
screening recommendations, for instance based on a technique like colonoscopy.  
Another direction would be to build a web-based tool for clinicians to use to estimate 
absolute risk for CRC based on a patient’s age and family history.  A further step 
along this path would be to integrate a tool such as this into an EMR along with 
actionable recommendations.  More generally, further work could explore how to 
communicate risk most effectively among clinicians and patients.  Finally, further 
exploration would be valuable to determine what types of research questions EMR 
data are best suited for and how the quality of clinical data sources may be improved 








SUPPLEMENTARY TABLES FOR POPULATION-BASED FAMILY  
 
HISTORY-SPECIFIC RISKS FOR COLORECTAL 
 






A.1: Familial relative risks for probands considering only first- and second-degree  
















0  0  NA 1,965,853 0.86 0.84  0.88
0  1  NA 224,609 1.05 0.99  1.11
0  2  NA 33,407 1.20 1.05  1.38
0  ≥3  NA 8527 1.48 1.11  1.93
1  0  NA 65,192 1.82 1.72  1.93
1  1  NA 16,760 2.12 1.90  2.35
1  2  NA 3776 2.31 1.80  2.93
1  ≥3  NA 1361 3.37 2.20  4.93
2  0  NA 4699 2.78 2.39  3.22
2  1  NA 1644 2.59 1.93  3.40
2  2  NA 433 6.26 4.16  9.05
2  ≥3  NA 190 9.63 4.97  16.82
≥3  0  NA 509 4.41 3.03  6.19
≥3  1  NA 221 8.63 5.59  12.74
≥3  2  NA 94 1.77 0.21  6.39










A.2: Familial relative risks for probands considering first-, second-, and  


















0  0  0 1,470,367 0.83 0.81  0.86
0  0  1 356,128 0.86 0.82  0.91
0  0  2 94,696 0.95 0.87  1.03
0  0  ≥3 44,662 1.08 0.97  1.20
0  1  0 132,580 0.95 0.88  1.03
0  1  1 57,850 1.09 0.98  1.21
0  1  2 20,321 1.33 1.13  1.55
0  1  ≥3 13,858 1.21 0.98  1.48
0  2  0 15,756 1.18 0.97  1.43
0  2  1 9199 1.12 0.84  1.45
0  2  2 4391 1.25 0.84  1.79
0  2  ≥3 4061 1.48 0.98  2.16
0  ≥3  0 2938 1.48 0.91  2.26
0  ≥3  1 2157 1.56 0.89  2.53
0  ≥3  2 1312 1.93 0.93  3.55
0  ≥3  ≥3 2120 1.02 0.41  2.09
1  0  0 41,369 1.76 1.63  1.89
1  0  1 15,008 1.90 1.70  2.12
1  0  2 5560 1.90 1.59  2.25
1  0  ≥3 3255 2.01 1.61  2.47





















1  1  1 4685 1.97 1.59  2.41
1  1  2 1882 2.50 1.87  3.28
1  1  ≥3 1357 3.28 2.44  4.31
1  2  0 1669 2.37 1.58  3.43
1  2  1 1006 1.98 1.15  3.17
1  2  2 523 2.70 1.44  4.62
1  2  ≥3 578 2.38 1.19  4.26
1  ≥3  0 453 2.79 1.12  5.76
1  ≥3  1 380 1.69 0.46  4.34
1  ≥3  2 206 5.32 2.14  10.96
1  ≥3  ≥3 322 5.20 2.24  10.24
2  0  0 2613 2.96 2.41  3.60
2  0  1 1197 2.24 1.59  3.06
2  0  2 528 1.77 0.97  2.96
2  0  ≥3 361 4.82 3.18  7.02
2  1  0 717 2.54 1.57  3.89
2  1  1 439 1.80 0.82  3.41
2  1  2 241 1.57 0.51  3.67
2  1  ≥3 247 4.67 2.72  7.47
2  2  0 172 6.71 3.67  11.26
2  2  1 95 5.64 1.83  13.16



























2  2  ≥3 78 7.05 2.59  15.34
2  ≥3  0 40 3.31 0.08  18.42
2  ≥3  1 48 11.96 3.26  30.62
2  ≥3  2 46 16.37 4.46  41.91
2  ≥3  ≥3 56 8.21 1.69  24.00
≥3  0  0 246 2.96 1.42  5.44
≥3  0  1 127 4.21 1.82  8.30
≥3  0  2 52 1.33 0.03  7.39
≥3  0  ≥3 84 9.63 5.26  16.15
≥3  1  0 98 12.39 7.08  20.12
≥3  1  1 36 2.41 0.06  13.45
≥3  1  2 28 10.04 2.07  29.35
≥3  1  ≥3 59 5.61 1.82  13.08
≥3  2  0 41 0.00 NA†  NA†
≥3  2  1 16 22.05 2.67  79.64
≥3  2  2 18 0.00 NA†  NA†
≥3  2  ≥3 19 0.00 NA†  NA†
≥3  ≥3  0 11 15.90 0.40  88.58
≥3  ≥3  1 11 7.19 0.18  40.05
≥3  ≥3  2 20 0.00 NA†  NA†
≥3  ≥3  ≥3 10 0.00 NA†  NA†
      †When the observed and expected numbers of affected probands are both 0, a confidence  





A.3: Familial relative risks for probands with affected first-degree relatives  










































































A.4: Familial relative risks for probands with affected second-degree relatives 






















































A.5: Familial relative risks for probands with various affected first-degree  


































(brother)  NA  NA  24,117  1.99  1.84  2.14 
≥1 affected 





(offspring)  NA  NA  18,644  3.06  2.76  3.38 
     
Affected mother  1 
(mother)  NA  NA  15,589  2.03  1.78  2.30 













≥1 (male)  NA  NA  49,716  2.08  1.96  2.21 













































NA  NA  46,180  2.12  2.00  2.26 
  
 























































0  0  0  (≥2M and 0P) OR (0M and ≥2P)  NA  NA  NA  NA  11,597  1.41  1.13  1.73    
0  0  0  ≥1 ≥1 NA NA  NA NA 5414 1.47 1.06  1.98    
             




0  0  0  0  0  0  ≥1  ≥1  NA  36,048  0.87  0.78  0.98 
N=36,072 before 
removing those with 
looped relatives 
79 
